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1. A Case Of Multifactorial Orthostatic Hypotension Complicated By Chemotherapy  
Associated Autonomic Toxicity 
 
Christopher Bender, MD, Amy Decket, MD 
  
 
Introduction: 
Autonomic neuropathy is known to occur as a side effect of some chemotherapy drugs, including 
cisplatin. This reports presents a patient with new onset of autonomic instability and orthostatic hy-
potension after receiving multiple rounds of cisplatin and gemcitabine chemotherapy. 
 
Case Presentation: 
An 81-year-old man with history of stage III lung cancer presented after a fall at home that occurred 
while getting out of bed in the middle of the night in the setting of recent malaise and poor oral fluid 
intake. His cancer was treated with surgical lobectomy and thoracic lymphadenectomy five months 
prior to his admission, and three rounds of chemotherapy with cisplatin and gemcitiabine. He had 
been admitted to the same hospital three days prior for weakness and back pain and was empirically 
started on tamsulosin for urinary retention and was discharged with a foley catheter in place.  
 
On presentation he was noted to have marked orthostatic hypotension, and during the first night of 
admission he had high blood pressures while sleeping, with systolic blood pressure greater than two 
hundred mmHg. Postural hypotension did not improve over the first twenty-four hours after multiple 
intravenous fluid boluses. He was managed by discontinuing exacerbating medications including 
tamsulosin and benadryl, as well as treatment with physical therapy, an abdominal binder, and mini-
mizing the amount of time spent supine. He was discharged on the fifth day of hospitalization after 
clearance by physical therapy. 
 
 
Discussion: 
Although this case initially appeared to be a straightforward case of orthostatic hypotension related 
to hypovolemia, it became more complicated when the patient continued to display orthostatic hypo-
tension after initial fluid resuscitation and discontinuation of associated medications. Further sug-
gesting autonomic dysfunction was an inconsistent response of heart rate in relation to hypotension, 
as well as markedly elevated systolic blood pressure readings at night while the patient was supine. 
While not a common side effect, there are prior documented cases of autonomic neuropathy in as-
sociation with cisplatin, which was determined to be the most likely etiology in this case, given the 
timeline of presentation. An additional factor complicating this case was the issue of addressing or-
thostatic hypotension in a patient with autonomic instability causing intermittent severe hypertension 
such that the use of midodrine was not an option. This required creative problem solving including 
the use of an abdominal binder and compression stockings in order to get the 
 
Link to Poster 
2. Mixed Signals:  A Case Of Hypothyroid-Induced Ogilvie’s 
 
Brieanna Brown, MD, Paula Wichienkeur, MD 
 
Ogilve's syndrome, or acute colonic pseudo-obstruction (ACPO), is characterized by acute dilation 
of the colon, in the absence of a mechanical lesion, which obstructs the flow of intestinal contents. 
Pseudo-obstruction typically occurs in the critically ill, though the underlying pathophysiology is 
poorly understood and the etiology is often multifactorial. We present a case of a 51-year-old mor-
bidly obese woman presenting with symptoms of severe hypothyroidism found to have massive 
acute colonic pseudo-obstruction.  
 
Case presentation:  
A 51-year-old African-American woman with BMI of 68, OSA, CHF, hypothyroidism and medica-
tion non-adherence presented with severe generalized weakness.  On admission she was found 
to have TSH >150 and undetectable free T4. The patient was started on oral replacement therapy 
but despite this developed acute encephalopathy several days into the admission. She was evalu-
ated for myxedema coma but lacked bradycardia, hypothermia and hyponatremia. Along with en-
cephalopathy, she had poor oral intake and mild nausea, but no vomiting or abdominal pain, and 
continued having regular bowel movements. CT chest abdomen and pelvis was obtained in the 
work up of her encephalopathy, which revealed massive dilation of the cecum measuring 17 cm 
with no obvious mechanical obstruction concerning for pseudo-obstruction. GI and surgical ser-
vices were consulted, and the patient was ultimately managed non-operatively with neostigmine 
given her comorbidities. Nasogastric and rectal tubes were placed for decompression and subse-
quent CT scans revealed decompression without perforation or re-obstruction. The patient was 
discharged several days later on thyroid replacement with normalization of her T4 and no evi-
dence of re-obstruction.  
 
Discussion:  
Acute colonic pseudo-obstruction typically occurs in hospitalized patients in severe illness or after 
surgery and is hypothesized to be caused by an autonomic imbalance resulting in a hypotonic 
bowel. This mechanism was originally hypothesized by Ogilvie, who originally suggested lack of 
sympathetic signaling in the colon1. Sympathetic excess rather than parasympathetic causes are 
felt to be the more likely etiology, as evidenced by ACPO being more prevalent in the critically ill 
with high sympathetic drive. Neostigmine, an acetylcholinesterase inhibitor and parasympathomi-
metic is commonly used to reverse pseudo-obstruction, further suggesting restoration of autonom-
ic balance as a central pathophysiological mechanism. Neostigmine should be used with caution 
and often requires ICU monitoring given risk of precipitating bradycardia and bronchospasm. Case 
series of ACPO point to critical illness, surgery, electrolyte imbalance as the most common caus-
es, but hypothyroidism is a rare cause of pseudo-obstruction. Hypothyroidism is a common condi-
tion and known to have several manifestations in the GI tract including esophageal dysmotility, de-
layed gastric emptying, and diminished colonic motility. This case represents the latter, which typi-
cally manifests as constipation, but instead presented as a life-threatening pseudo-obstruction 
which was masked by encephalopathy, body habitus, and lack of prominent abdominal physical 
examination findings. When conservative management fails, or the cecum exceeds 12cm, typically 
decompressive colonoscopy or surgery is warranted. In this case, given the patient’s operative risk 
factors, chemical decompression with neostigmine was administered and the patient improved.  
 
Link to Poster 
3.  HIV-Associated Burkitt Lymphoma 
 
Rahwa Ghebremichael, MD, Amy Dechet, MD 
 
A 24-year old woman with history of homelessness, HIV (off ART for 3 months, CD4 596 and 32%, 
HIV 55,800), chronic hepatitis C (untreated without cirrhosis) and active IVDU with heroin 
and methamphetamine presenting with 1 month of progressive fevers, chills, epigastric pain and 
nausea.  
 
She was found to be tachycardic, tachypneic, febrile on admission with worsening anemia (Hgb 9, 
baseline 11) but otherwise normal labs. Exam was notable for new systolic heart murmur which 
prompted a TTE and empiric broad spectrum antibiotics for presumed endocarditis in the setting of 
her IVDU.  To our surprise, the TTE revealed no vegetations and blood cultures were negative for 
growth.  Fortunately, we had also ordered a CT abdomen pelvis at the time of admission which 
demonstrated diffuse gastric thickening with evidence of omental seeding with nodularity and sple-
nomegaly. A gastric biopsy obtained the following day demonstrated DLBCL with FISH later re-
vealing a high grade Burkitt lymphoma, EBV+. PET scan was notable for diffuse tumor burden. 
She was started on Short Course EPOCH-RR during her admission with a guarded prognosis, and 
concern for TLS and gastric perforation due to the extensive tumor burden in her abdomen.  Thus 
far, she has tolerated 3 of the anticipated 4-6 chemo cycles with relatively minor complications by 
comparison including bradycardia, frequent NSVT and neutropenia necessitating adjustments to 
her chemotherapy regimen/schedule.  Her substance use has remained an ongoing challenge.  
 
Learning Points:  
- HIV is associated with an increased risk for malignancies, lymphoid in particular, as compared to 
the general population 
- Although the incidence of non-Hodgkin’s lymphoma (NHL) in the setting of HIV infection has 
markedly decreased since the introduction of combination antiretroviral therapy (cART), HIV-NHL 
still remains a leading causes of AIDS-related deaths 
- The most common subtypes of HIV associated NHL are diffuse large B-cell lymphomas 
(DLBCLs) and Burkett’s lymphomas (BLs) and are associated with CD4 counts 
- Burkitt’s lymphoma (BL) is a highly proliferative NHL deriving from B cells and with characteristic 
oncogenic pathways, including translocation in the MYC gene.  
- BL in HIV-positive patients constitutes 10-35% of AIDS defining lymphoma depending on the lit-
erature, as compared to 1-2% of NHL in the general population  
- More than 2/3rd patients with AIDS-related lymphoma present with advanced lymphoma stage, B 
symptoms, extra nodal involvement and involvement of usual sites including soft tissue and body 
cavity. 
- HIV positive patients with BL on CHOP like regimens respond poorly to this therapy. R-EPOCH 
might be an alternative treatment that offers better response in HIV associated-BL.  
- It is important to include malignancy in the differential diagnosis of patients with HIV that present 
with subacute illness. 
 
 
 Link to Poster 
4. The Dangers Of Gardening –  Nocardia Infection In An Immunocompromised Patient 
 
Gerald Hutfles, DO, Justin Jin, MD 
 
Introduction:   
Nocardia is a gram-positive, partially-acid fast, aerobic, branching bacillus that can be found in soil 
and water.  It is typically an opportunistic pathogen, with most infections occurring in the immuno-
compromised.  Disease can be localized or disseminated, preferring pulmonary, nervous, and cu-
taneous tissues.  Optimal antimicrobial therapy depends on speciation of the isolate, as Nocardia 
may exhibit variable antimicrobial susceptibility.  A high clinical suspicion and appropriate empiric 
antimicrobial therapy is necessary.  This clinical case highlights the importance of these two fac-
tors, as well as the difficulties associated with treatment of disseminated Nocardiosis in the immun-
ocompromised patient. 
 
Case Presentation:   
A 56-year-old Filipino-American male with a history of renal transplant in 2008 due to Membranop-
roliferative Glomerulonephritis on chronic immunosuppression presented with a three-month histo-
ry of recurrent cough and chills, worsening in the past week.  He had sought medical care twice 
during this period and had received full courses of Doxycycline and Amoxicillin-Clavulanate with 
intermittent improvement.  He then presented hypoxic, febrile, and tachycardic to the emergency 
room, with a right upper lobe consolidation and right posterior axillary pain.  Respiratory and blood 
were drawn, as well as Mycobacterium Tuberculosis sputum cultures given recent travel to the 
Philippines.  Patient was then started on Ceftriaxone and Azithromycin for treatment of community-
acquired pneumonia.  He gradually improved over the next few days, but after several days, blood 
and sputum cultures were positive for what was found to be Nocardia nova.  He also had right axil-
lary and calf abscesses that were subsequently drained and growing Nocardia nova.  MRI of his 
brain, CT of his abdomen, and transthoracic echocardiogram were performed to evaluate the ex-
tent of disease, and all were negative.  He was transitioned to Imipenem and Trimethoprim-
Sulfamethoxazole for treatment of disseminated Nocardiosis.  While on therapy, he developed se-
vere hyponatremia, which was thought to be due to current treatment.  He was transitioned to 
Ceftriaxone based on available sensitivities and had improvement of his drug toxicities and symp-
toms on this regimen.  After six weeks of IV antibiotics, he was transitioned to oral Cefpodoxime 
for an expected twelve months of therapy.  Furthermore, nephrology discontinued his Azathioprine 
to reduce his immunosuppression, and his graft has continued to function well. 
 
Discussion: 
Nocardia is a ubiquitous organism that uncommonly becomes pathogenic to humans, but infec-
tions can be serious, especially in the immunocompromised.  It is important to have a high clinical 
suspicion in immunocompromised patients.  As more information emerges about this genus, it is 
important to fully speciate and obtain antimicrobial sensitivity patterns, which can be quite variable.  
Duration of treatment in immunocompromised patients and those with CNS infections is at least 
one year.  There are no guidelines for primary prophylaxis for Nocardiosis.  Some experts recom-
mend indefinite secondary prophylaxis in patients with ongoing immunosuppression. 
 
Link to Poster 
5.  When Less Virulent Becomes Virulent!! 
An Atypical Presentation Of Streptococcus Viridians 
 
Samreen Kahn, MDDS, Stavan Patel, MS, MD 
 
Introduction:   
There are several cardiac and non-cardiac causes and risk factors for the development of infective 
endocarditis (IE) in young healthy adults. Some risk factors include prior IE, history of valvular or 
congenital heart disease, IV drug use, indwelling intravenous lines, immunosuppression, or a recent 
dental or surgical procedure. Most two common sites of IE are mitral and aortic valve. We present a 
case of a 45-year-old man with no-known risk factors, who presented with respiratory distress and 
was found to have streptococcal viridians (SV) endocarditis.  
 
Case Presentation:   
A healthy 45-year-old male presented with a four-day history of acute dyspnea and new-onset of 
fevers and chills for 24 hours before arrival.  He denied any chest pain, dizziness, palpitations, LOC, 
weakness, increasing LE edema, or palpations. Patient denied any recent travels, prolonged non-
ambulatory state, recent sick contacts, IV drug abuse, high risk sexual activities, no-known personal 
cardiac history, no recent dental manipulation. While in ED, he reported new onset of chest heavi-
ness, and a non-productive cough. Vitals: T 37.2 C, BP 125/9, P 122, RR 26. EKG showed sinus 
tachycardia with non- specific ST&T wave abnormalities/No prior ECG where available to compare. 
Troponin 64 ng/L. ABG pH 7.230, PCO2 27.4 mmHg, PO2 82.1 mmHg. A-a gradient calculated to 
be greater than 200. CXR showed pulmonary vascular congestion. CTPA for PE was deferred as 
patient could not remain supine during examination secondary to worsening respiratory status. Pa-
tient was moved to medical ICU, with rapid worsening of respiratory status requiring intubation. Ur-
gent bronchoscopy revealed diffuse alveolar hemorrhage consistent with severe acute respiratory 
distress syndrome (ARDS) with multifocal pneumonia. On initial presentation IE was not excepted 
and patient was treated for viral and bacterial causes of ARDS. Echocardiogram showed aortic 
valve insufficiency with questionable vegetation with leaflet disruption. Subsequently blood cultures 
showed gram-positive cocci. Given the combination of aortic insufficiency (AI) and gram-positive 
cocci IE speculated which was soon followed by aortic valve replacement with intraoperative finding 
of aortic intra-annular abscess. Clinical course was complicated with cardiogenic shock and multi-
organ failure. Blood cultures subsequently grew SV. 
  
Case Discussion  
Despite advances in medical, surgical and critical care interventions, IE remains a life-threatening 
illness. SV is not uncommon but are routinely seen in those with underlying heart disease and den-
tal manipulation. SV is responsible for 40-60% of IE in normal valves [3, 4] and patients (young 
males and over 45 years of age) usually with mitral valves. It is commonly associated with heart fail-
ure and lesion such as peri-annular abscesses, fistulas, or pseudo-aneurysms with risk of mortality 
at 15% [1, 2]. Diagnosis may be difficult given no risk factors, non-specific symptoms but does not 
exclude this pathogen as a cause. 
 
Link to Poster 
6. A Case Of Spontaneous Intercostal Artery Hemorrhage 
 
Chang Lee, MD, Veronica Schims, MD, Craig Riley, MD 
 
Introduction:   Spontaneous intercostal arterial bleeding is rare and usually related to trauma.  We 
describe a patient with a history of cirrhosis and coagulopathy admitted with sepsis who spontane-
ously developed an expanding extrathoracic hematoma and subsequent hypovolemic shock requir-
ing arterial embolization. 
 
Case Presentation:  50-year-old male with a past medical history of alcoholic liver disease, esoph-
ageal varices, chronic coagulopathy, type 2 diabetes and hypertension on lisinopril was admitted to 
hospital with decreased urine output, dizziness, poor PO intake and lower abdominal discomfort.  
On exam, blood pressure was 80/50 mmHg and he was encephalopathic with otherwise unremark-
able physical exam.  Labs showed a normal lactate, sodium 117, hemoglobin 11 g/dL, INR 1.5, ele-
vated creatinine and severe metabolic acidosis.  CT abdomen and pelvis showed nonspecific dif-
fuse colitis but no source of infection.  His decompensated cirrhosis and acute kidney injury was 
thought due to poor oral intake and Lisinopril use.  He developed worsening renal function and aci-
dosis.  His urinary output diminished leading to volume overload.  He was then transferred to the 
intensive care unit for placement of right-sided internal jugular temporary dialysis catheter for initia-
tion of hemodialysis, which was without complications.  On hospital day five, he developed a precip-
itous drop in hemoglobin from 8.7 to 6.0 g/dL and a new right back pain with swelling.   A CT 
abdomen/pelvis revealed a large hematoma along the posterior right hemithorax involving the latis-
simus dorsi extending from the level of the 1st to 10th rib measuring 30 cm x 5 cm.  No reports of 
trauma and no invasive procedures occurred to explain the hematoma. The patient required multi-
ple transfusions of red blood cells, platelets and fresh frozen plasma and the bleeding, expected to 
tamponade itself, continued.  He underwent emergent arterial embolization with coiling of three in-
tercostal arteries and then successful ultrasound-guided evacuation of the remaining large extratho-
racic hematoma.   
 
Discussion:  This is a rare case of spontaneous intercostal arterial bleeding.  Literature review 
shows spontaneous intercostal artery hemorrhage is rare.  Cases of intercostal artery hemorrhage 
more commonly involve trauma, and rarer still, associations with neurofibromatosis type 1 and co-
arctation of the aorta.  There is one case report of an incident occurring after hemodialysis, which is 
the case in this patient.  Other case reports include patients with hepatocellular carcinoma, inter-
costal artery aneurysm while in flight, SLE with antiphospholipid syndrome, Dengue fever, as well 
as causes entirely unknown.  Our patient had underlying liver disease with chronic coagulopathy 
and mild thrombocytopenia as risk factors for spontaneous bleeding, other considerations included 
use of low molecular weight heparin or heparin use with hemodialysis, but no inciting factor such as 
trauma or surgical intervention.  When active, uncontrollable bleeding is observed from intercostal 
arteries, early arterial embolization should be considered.  
 
 
  
7. Autoimmune Hemolytic Anemia In Chronic Lymphocytic Leukemia 
 
Kelley Newton, MD, Janan Markee, MD 
 
 
Patients with chronic lymphocytic leukemia have a 5-10% risk of developing autoimmune compli-
cations, the most common of which is autoimmune hemolytic anemia. Here we present a case of 
AIHA in a patient with suspected CLL that underscores several of the diagnostic and treatment 
challenges unique to this process.  
 
A 79-year old man with a history of hypertension, atrial fibrillation, type 2 diabetes and hypothy-
roidism was undergoing workup for suspected CLL due to a persistent leukocytosis. He then pre-
sented to his primary care physician after several weeks of worsening exertional chest pain and 
dyspnea. On exam, he was noted to be confused as well as mildly jaundiced and was sent to the 
Emergency Department for work up with a specific concern for ACS given his presenting symp-
toms. Cardiac workup was unremarkable with a negative troponin, normal BNP and no changes 
on EKG. Pulmonary CTA was negative for pulmonary embolism. However, his lab work revealed 
an acute macrocytic anemia with a Hgb of 5.1 as well as a Total bilirubin of 4.1. Additional lab 
work revealed a significantly decreased haptoglobin, elevated reticulocyte count and IgG/
complement positive DAT. CT abd/pelvis showed splenomegaly. The patient was admitted, 
placed on high dose steroids and 2 units of packed red blood cells were ordered. After some de-
lay due to an inability to find compatible blood, he received several ABO and RhD matched units. 
After several days, his hemoglobin stabilized and reticulocyte count and Tbili down trended. He 
was discharged on high dose steroids to be tapered down once his Hgb>10 over the course of 4-6 
months, with outpatient oncology follow up.  
 
This case highlights several important points in the diagnosis and treatment of AIHA in CLL. First-
ly, it is important to note that in virtually all cases of warm AIHA cross-matches will be incompati-
ble as auto-antibodies will recognize blood group antigens and react to the vast majority of donor 
red cells. Consequently, ABO and RhD matched blood should be given in severe anemia requir-
ing urgent blood transfusion. The blood should be given slowly with careful monitoring for transfu-
sion reaction, though the risk of this is low. Another important consideration in the workup and 
treatment of AIHA is the substantial risk of VTE in these patients. Given the presentation of dysp-
nea in this patient, ruling out concomitant PE is especially crucial. Lastly, the relatively high rate of 
AIHA in CLL workup for hematologic malignancy should be considered in patients presenting with 
apparently idiopathic AIHA. 
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8. Wrap It Up – Sexually Transmitted Primary Cytologmegalovirus Proctitis  
In Immunocompetent Host:   A Case Report 
 
Vanessa Nwaokocha, MD, Brinton Clark, MD, Ronald Dworkin, MD 
 
Background:   In persons who presents with fever, rectal pain and bleeding, CMV proctitis should 
be considered if other workup is negative, especially if recent unprotected anal receptive inter-
course. 
 
Case Presentation:  A 26-year-old bisexual man presented with chief complaints of fever, malaise, 
rectal pain, and rectal bleeding after anal insertion of foreign body. He initially denied any unprotect-
ed sexual intercourse. CBC, CMP, stool pathogen, rectal gonorrhea, and rectal chlamydia were un-
remarkable.   He returned after 1 week with the similar complaints, however admitted to unprotect-
ed anal receptive intercourse a month prior. His vitals were notable for temperature of 102 with 
tachycardia to 108. Labs were significant for WBC 6.6, atypical lymphocytes 22%, ALP 173, AST 
72, and ALT 146. CT AP with contrast showed perirectal fat stranding, rectal wall thickening, and 
several perirectal lymph nodes. Syphilis and HIV testing were negative. Given concern for viral 
proctitis from HSV, he was treated with valacyclovir.  Flexible sigmoidoscopy showed diffuse severe 
inflammation with deep ulcerations consistent with severe ulcerative proctitis extending 15cm into 
the rectum. Biopsies were positive for CMV on immunohistochemical staining and viral culture.  
CMV serology was positive for IgM, IgG, and viral DNA. The patient was treated with ganciclovir for 
primary CMV proctitis for a 14-day course.  
 
Conclusion:  Proctitis typically presents with rectal bleeding, rectal pain, anorectal itching, cramps/
tenesmus, or discharge from the anal canal. Common sexually transmitted infectious causes in-
clude chlamydia, gonorrhea, syphilis, HSV.  CMV has also been shown to be a cause of procto-
colitis in immunocompromised patients with HIV. Though rare, primary CMV in an immunocompe-
tent host can cause proctitis and has been reported in persons who engage in unprotected anal in-
tercourse, especially MSM.  
 
Diagnosis of primary CMV proctitis requires multiple diagnostic tests in the right clinical setting.  De-
tection of CMV IgM, a four-fold increase in CMV IgG done 2-4 weeks apart, and sigmoidoscopy 
showing rectal mucositis or ulceration are suggestive of CMV proctitis. In our patient, his atypical 
lymphocytes and elevated liver function tests were also suggestive of CMV. Biopsy showing pres-
ence of inclusion bodies or basophilic intranuclear inclusions and immunohistochemical staining 
that is positive for CMV are confirmatory.  
 
Treatment for primary CMV proctitis has not been well defined and is typically conservative man-
agement though we chose to treat with ganciclovir given severity of symptoms. In conclusion, a 
mononucleosis-like illness with rectal bleeding and/or pain after unprotected anal intercourse can 
suggest a diagnosis of CMV proctitis. 
 
Link to Poster 
9. A Rare Case Of Metastatic Insulinoma In A Patient With Huntington’s Disease 
 
Olesya Petrenko, DO, Brinton Clark, MD, FACP 
 
A 49-year-old female with past medical history of Huntington’s disease presents to the ED after 
being found unresponsive at her assisted-living facility. She was noted to be hypoglycemic with a 
glucose of 21 and responded to dextrose. For the past several months, patient had symptoms of 
dizziness, tremors. She has no history of diabetes, and only home medication is Zyprexa.  Patient 
required D10 drip to maintain glucose levels. Given patient’s psychiatric history, there was concern 
for surreptitious use of diabetic medications. Labwork showed an insulin level of 163 and an ele-
vated C-peptide of 7.0 consistent with endogenous insulin secretion. Patient underwent a 72-hour 
fasting protocol which revealed a glucose of 23, C-peptide of 4.1 and insulin of 101, undetectable 
beta-hydroxybutyrate levels and pro-insulin level of 782 (normal <8), which are consistent with a 
diagnosis of insulinoma. She was started on diazoxide, which diminishes insulin secretion, to treat 
the hypoglycemia. Patient underwent a pancreas CT protocol which showed multiple hypervascu-
lar hepatic masses up to 9 cm and one 4 cm mass in pancreatic tail concerning for metastasis. Pa-
thology revealed metastatic well-differentiated neuroendocrine tumor grade 3. She was not a can-
didate for surgical resection of tumors and she was started on Octreotide 200 mcg TID. Patient 
underwent two Y90 therasphere radioembolization treatments, 2 months apart with improvement 
of hypoglycemia and discontinuation of diazoxide. Patient remains on Octreotide LAR injection 
every 4 weeks with frequent glucose monitoring. 
 
Insulinoma, although rare, occurs in 1-4% of the population and is the most common type of func-
tional neuroendocrine tumor of the pancreas. It secretes insulin which results in hyperinsulinemic 
hypoglycemia. Diagnosis involves persistent hypoglycemia with glucose <50 mg/dL, neuroglyco-
penic symptoms and prompt relief after glucose administration. Gold standard diagnosis is a 72-
hour fast and measurement of plasma insulin, C-peptide and pro-insulin, which detects 99% of in-
sulinomas. After lab confirmation, imaging is necessary to localize the tumor with either CT, MRI 
or EUS. Surgical resection is curative in most patients. Other treatment modalities include injection 
of octreotide, EUS-aided alcohol ablation, radio-frequency ablation or embolization of insulinoma, 
as well as targeted therapy with everolimus or sunitinib.  
 
Malignant insulinomas are extremely rare and often invade into surrounding soft tissue or have 
lymph node or liver metastasis. They are usually unresectable and require targeted therapy.   
 
We present the case of a 49-YO patient with Huntington’s disease who presented with severe per-
sistent hypoglycemia secondary to metastatic insulinoma.  Diagnosis of insulinoma is often de-
layed or missed as symptoms may be attributed to psychiatric, cardiac or neurological disorders or 
medication misuse. Clinicians should be aware of insulinoma as a cause of life-threatening hypo-
glycemia. 
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10.  Soft Rock – When Blasting It Doesn’t Work 
 
Mark Schneider, MD, Jesse Powell, MD 
 
 
Case-History of Present Illness:   68-year-old female presents with several days of malodorous urine and 
fevers. Brought to the ED by her daughter who diagnosed urinary tract infection (UTI) due to the distinct 
urine odor. 
No hematuria, dysuria, retention, or incontinence. 
 
Past Medical History:  Recent hospitalization for UTI with culture that grew P.mirabilis, completed course of 
cefdinir, with follow-up culture ordered by PCP that grew extended-spectrum beta lactamase (ESBL) E.coli. 
 
Physical Exam and Vital Signs:  Vitals: 115/48, 101, 38°C, 18, 93% without supplemental oxygen. 
• Lumbar spine tenderness, no CVA tenderness. Large area of erythema of right inner thigh and chronic low-
er extremity edema. Otherwise a non-focal exam. 
 
Labs and Imaging:  Procalcitonin 2.3, UA - packed bacteria/WBCs/3+ leukocyte esterase, WBC - 17.5, and 
urine culture with >100,000 CFU/mL ESBL E.coli.  CT abdomen : Staghorn calculus within the lower pole 
calyces and renal pelvis of the right kidney. Heterogenous low density material within the mid and upper 
pole calyces suspicious for xanthogranulomatous deposits.  Renal function evaluated via nuclear medicine 
kidney flow and function with diuretic showing: No urinary obstruction. Asymmetrical renal activity with 73% 
left kidney and 27% right kidney. 
 
Clinical Course:  IV antibiotics while undergoing work-up.  Urology consulted and recommended stone re-
moval due to recurrent UTIs with same organisms despite treatment.  Went to OR for stone removal. Proce-
dure abandoned due to unexpected finding of “white exudate renal collecting system mass” with concern for 
an organized abscess or fungal ball.  Tissue sample sent for culture and pathology. Culture grew Proteus 
mirabilis/penneri. Pathology report stated degenerative amorphous material with rare inflammatory exudate 
and fibrinoid hemorrhagic exudate. Macroscopic appearance similar to picture at right.  Patient readmitted 
for planned percutaneous nephrolithotomy. The stone was successfully removed by manual grasping and 
removal in pieces.  Renal Matrix (Proteinaceous) Stones. 
 
Rare:  First described in 1908.  50 published cases between 1908-1981. 
 
Risk Factors:  Female.  History of urinary tract infections, chronic renal failure, hemodialysis. 
• Infection with P.mirabilis or E.coli.  Proteinuria. 
 
Presentation:  Similar to those with calcium nephrolithiasis – flank pain and UTI. 
 
Diagnosis:  Possible to suspect/diagnose by imaging.  Usually made at the time of surgery. 
 
Treatment Surgery:  Surgical removal is necessary – emergently if obstruction or urgently for source con-
trol when associated with a UTI.  Percutaneous or uteroscopic approach – Shockwave lithotripsy does not 
work. 
 
Prevention of recurrence:  Prophylactic antibiotic use.  Acidification of the urine. 
 
Conclusions 
• Rare and easily overlooked/mistaken for calcium based renal calculi 
• Diagnosis often at the time of surgery 
• Can cause obstruction and renal failure 
• Surgical/urologic intervention is needed for removal. Refractory to shockwave lithotripsy. 
• Antibiotics and/or acidification of the urine may help prevent recurrence. 
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11. A Perplexing Case Of Episodic Abdominal Pain  
And The Role Of Mast Cells Gastroenteritis  
 
Hayden Smith, MD, Mari Kai, MD 
 
 
 Here we present a case of chronic intractable vomiting and diarrhea of unknown cause, and intro-
duce the relatively new entity of mast cell gastroenteritis.  
 
Our patient is a 38-year old female with PMH of seronegative rheumatoid arthritis, mixed connec-
tive tissue disorder, and several recent hospitalizations over the past 4 months at outside hospitals 
for suspected colitis with associated vomiting and diarrhea. Current symptoms include 4 days of 
nausea with intractable vomiting, and 2 days of rectal fullness with mucoid rectal discharge. Previ-
ous workup at outside hospitals included multiple abdominal CT scans, flexible sigmoidoscopy, co-
lonoscopy, and exploratory laparotomy. Prior to admission no definitive diagnosis were identified 
for her symptoms, despite extensive workup. Possible causes considered include inflammatory 
bowel disease, irritable bowel disease, hereditary angioedema, and small vessel vasculitis. 
 
On admission, our physical exam showed no abnormalities including normal rectal exam. CT scan 
showed inflammation in the colon particularly in the rectum.  A flexible sigmoidoscopy showed only 
edematous appearance of the colon without bleeding, ulcerations, or erythema.  Biopsies were ob-
tained, and initial pathology was non-specific. Special stains of the rectal tissue showed increased 
CD117+ cells at the lamina propria suggesting mast cell gastroenteritis (MCG) as the cause of her 
symptoms. She was treated with IV steroids until she could tolerate oral budesonide on discharge. 
 
MCG is defined as the abundance of mast cells at the lamina propria along the GI tract. Release of 
inflammatory mediators by these cells cause gastrointestinal mucosal inflammation leading to 
symptoms of nausea, vomiting, diarrhea, and abdominal pain. The relatively new and evolving di-
agnosis of MCG can be part of a larger systemic process or as the patient’s primary problem. 
Treatments include antihistamines, cromolyn, and steroids. Knowing when to test for MCG and 
how to interpret the results given a clinical scenario can be helpful in understanding the cause of a 
patient’s symptoms. In the setting of this case we can better understand this clinical reasoning be-
hind MCG and more effectively treat our patient and her underlying GI mastocytosis. 
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12. A Case Of Gluten-Induced Delirium:  
Using Capsule Endoscopy To Diagnose Occult GI Bleeding 
 
Rachael Starcher, MD, Lisa Sanders, MD 
 
Introduction:  
Despite an increasing prevalence of celiac disease worldwide, many patients remain undiag-
nosed, putting them at risk for late stage complications of unidentified and untreated celiac dis-
ease. Ulcerative jejunoileitis is a rare cause of occult GI bleeding seen only in refractory celiac dis-
ease or in atypical celiac disease at the time of diagnosis. When left untreated, ulcerative jejunoil-
eitis can lead to bowel perforation, blood loss anemia, and T-cell lymphoma. 
 
Case Presentation:  
An 81-year-old male presented with hypoactive delirium of a few hours duration. His partner no-
ticed inattentiveness, confusion, and inability to complete his daily activities the day of admission. 
Review of systems was otherwise negative. He had a previous stroke a year prior, sick sinus syn-
drome with a pacemaker, and myocardial infarction with stent placement just over 6 months be-
fore admission. On admission, he was tachycardic to 101, with normal blood pressure and mild 
anemia (hemoglobin 12.1 g/dL, from 14.1 g/dL a month prior). Infectious work up including viral 
panel, white count, procalcitonin, and urinalysis was negative. Creatinine was near the patient’s 
baseline (1.2 mg/dL), but BUN was up to 82 mg/dL from 17 mg/dL a month prior. Head CT was 
negative for any new process. 
 
Initial work up revealed positive fecal occult blood, but subsequent evaluation with upper endosco-
py and colonoscopy found no cause. Hemoglobin trended downward and the patient received 
blood transfusions. Small bowel capsule endoscopy, however, showed evidence of ulcerative jeju-
noileitis, with subsequent duodenal pathology significant for gluten sensitive enteropathy (celiac 
disease), Marsh type 3 (destructive type). Serum studies showed elevated tissue transglutami-
nase IgA, anti-gliadin antibody IgG and IgA. He was started on a gluten free diet and has shown 
improvement in antibodies, stabilization of anemia, and significant improvement in mental status. 
Repeat capsule endoscopy has also shown improvement in jejunal ulceration. 
 
Discussion:  
Capsule endoscopy is an excellent diagnostic tool when the source of a GI bleed cannot be found 
with EGD or colonoscopy. Not only does it have greater than 96% positive predictive value for di-
agnosing celiac disease, it can also identify other small bowel disorders including Crohn’s dis-
ease. This case highlights the importance of diagnosing celiac disease as when left untreated, 
complications such as ulcerative jejunoileitis can lead to bowel perforation, blood loss anemia, 
and T-cell lymphoma; however it can be effectively treated with a gluten free diet. 
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13.   Vocal Cord Dysfunction Masquerading As Exercise-Induced Bronchoconstriction 
 
Brandon Tempte, DO, Meera Jain, MD, FACP, Jason Wells, MD  
 
Intro:  
Exercise-induced bronchoconstriction (EIB), previously exercise-induced asthma, has a high prev-
alence in the community. Patients with these symptoms are typically diagnosed clinically and treat-
ed empirically with pre-exercise albuterol. Eucapnic voluntary hyperventilation (EVH) has been 
used to objectively test for EIB and can help to confirm the diagnosis, as well as rule out other 
causes such as exercise-induced vocal cord dysfunction (EIVCD), which may mimic EIB. 
 
Case Description:  
A 42-year old female with no significant medical history, presented with dyspnea and chest tight-
ness, starting 20-30 minutes into running exercise. Symptoms started five years ago. She was giv-
en an albuterol inhaler and later montelukast by her PCP, without improvement. She was referred 
to pulmonology and underwent EVH testing. Testing was negative for EIB. However, the inspirato-
ry limb of her flow volume loop was flattened on post-exercise spirometry. She was subsequently 
referred to ENT for videolaryngoscopy (VLS) to rule out EIVCD. VLS showed paradoxical vocal 
cord function with rapid and forced breathing, and the diagnosis of EIVCD was made. Albuterol 
and montelukast were discontinued. She underwent outpatient speech language therapy with sig-
nificant improvement in her symptoms.  
 
Discussion:  
EIB has a prevalence of 5-20% in the general population and may affect up to 90% of patients with 
symptomatic asthma. It typically presents as shortness of breath, chest tightness, and cough 10-15 
minutes after initiation of exercise. In a community setting, EIB is typically diagnosed and treated 
based on symptoms alone. However, not all patients with these symptoms have EIB, and may fail 
expensive inhaler treatments. EVH can help to objectively confirm the diagnosis of EIB and help 
rule out other potential causes such EIVCD. 
 
EVH requires the patient to breath at a high target minute ventilation to simulate exercise while 
breathing a set gas mixture to maintain eucapnia. Spirometry is then performed at 3, 5, 10, 15, and 
20 minutes to evaluate for a decrease in post-exercise FEV1 >10%, indicating EIB. It is considered 
by many literature sources to be the “gold standard” of EIB diagnosis when compared to exercise 
testing and methacholine challenge.  
 
Recent studies utilizing EVH have shown increasing evidence that EIVCD may be a more common 
cause of exercise-induced symptoms than previously thought. EIVCD can be suggested on EVH 
by flattening of the inspiratory flow volume loop on post-exercise spirometry. EIVCD can then be 
confirmed by video laryngoscopy (VLS). EIVCD is treated with speech language therapy, which is 
much different from EIB. Utilizing EVH to objectively diagnose EIB can likely lead to a decrease in 
inappropriate medication use and healthcare utilization with the added benefit of more accurate 
treatment modalities. 
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14.  Be Careful What You Screen For: 
An Incidental Finding Of Tracheobronchial Amyloidosis 
 
Emma White, MD, Tricia James, MD, Vikram Sahni, MD, Jesse Powell, MD 
 
Introduction: The 2011 National Lung Screening Trial (NLST) demonstrated a reduction in morbidi-
ty and mortality with LDCT compared to CXR. In 2013 the USPSTF began recommending CT scan 
for lung cancer screening in appropriate patients but, the 2015 National Health Interview Survey 
(NHIS) demonstrated that less than 5% of eligible patients received screening. The NLST also 
demonstrated a high rate of false positives, incidental findings, and the need for further invasive 
testing. When deciding to screen, patients and providers are tasked with reconciling these risks and 
benefits. In this case, we explore one patient’s incidental findings, and the work-up that ensued. 
 
Our Case: Our patient is a 70-year old female with PMHX of COPD (GOLD 1) who suffers from 
dyspnea with exertion, and cough. The patient did not tolerate LAMA therapy but her symptoms im-
proved with the addition of an ICS/LABA inhaler. She has had 1-2 COPD exacerbations per year. 
She has a 54-pack year smoking history and quit smoking 2 years ago. In accordance with USPSTF 
guidelines and with shared decision making, the patient was referred for lung cancer screening with 
LDCT. 
 
LDCT revealed thickening of the patient’s right and mainstem bronchi, and trachea. In light of this, 
the patient was referred to pulmonology for bronchoscopy. Bronchoscopy demonstrated irregular 
thickening and heaped pink mucosa. Biopsies were examined by a pathologist who determined the 
tissue to be amyloid. Upon follow up in primary care clinic, the tissue samples were located and 
again sent for amyloid sub-typing which identified AL amyloid. With this finding, the patient required 
subsequent testing with free light chains, SPEP, and UPEP to rule out a plasma cell dyscrasia. Fi-
nally, a fat pad biopsy was ordered to evaluate for systemic amyloidosis.  With all of these tests 
negative, the patient could be diagnosed with localized pulmonary AL amyloidosis & specifically tra-
cheobronchial amyloidosis. This condition is managed symptomatically and does not require sys-
temic chemotherapy.  
 
Discussion: In this case, we explored the diagnosis of a patient with central airway obstruction due 
to amyloidosis found incidentally during lung cancer screening.  In our patient, the incidental finding 
of central airway obstruction required further testing with bronchoscopy, pathology, mass spectrom-
etry, SPEP, UPEP, serum free light chains, and a fat pad biopsy which were ultimately negative. 
The high rate of false positive screens and the need for subsequent testing are concerns physicians 
must address with their patients when recommending lung cancer screening CT. This should be 
balanced with the potential for reduced mortality and morbidity with CT screening, through higher 
cure rates, less invasive lung resection, and increased rates of smoking cessation. 
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15.  Beck’s Tetrad?  
Adding POCUS To The Clinical Exam For Pericardial Tamponade Improves Diagnostic  
Accuracy In Obstructive Shock 
 
Cody Wiench, MD, Benjamin Pedroja, MD 
 
Introduction:  
Obstructive shock due to tamponade is an important, but rare, cause for sudden cardiovascular col-
lapse. Accurate treatment requires prompt (and correct) diagnosis. Bedside echocardiogram can 
provide rapid and accurate diagnosis, however the physical exam can provide important clues to 
consider tamponade. In patients with conditions that predispose them to pericardial disease, such 
as SLE, one must have a high index of suspicion for tamponade when patients suddenly de-
compensate.  
 
Case Presentation:  
A 27-year old woman with a history of SLE on chronic immunosuppression, pulmonary hyperten-
sion and chronic pain presents to the Emergency Department with subjective fevers to 40C, dia-
phoresis and sudden onset back pain. Vitals in the ED were impressive for heart rate of 106, blood 
pressure of 92/67, respiration rate of 10. Labs and imaging were unremarkable. Pt admitted to hos-
pital for potential sepsis of unclear cause in an immunosuppressed patient and was started on van-
comycin and piperacillin-tazobactam. On day 5 of hospitalization, a rapid response was called due 
to sudden onset of heart rate to 150, respiration rate to 24, blood pressures of 80s/50s and severe 
chest pain. Physical exam at that time was notable for muffled heart sounds and pulsus paradoxus. 
Bedside ultrasound demonstrated a large pericardial effusion resulting in cardiac tamponade. 
Emergent pericardial fluid drainage was preformed, draining 70 cc of fibrinous, bloody fluid. After 
procedure, the patient had rapid normalization of hemodynamics. Pericardial fluid analysis was per-
formed, but nonspecific. It is thought that the effusion was secondary to SLE, and the patient was 
discharged to home in stable condition.  
 
Discussion:  
Cardiac involvement in SLE is thought to occur in more than 50% of SLE patients, however tam-
ponade is much rarer with an estimated incidence of <1% in a review series. Tamponade portends 
a poor prognosis in SLE patients. During acute cardiovascular collapse in SLE, one much have a 
rapid approach to evaluating for tamponade. Pulsus paradoxus is one of those maneuvers; in one 
prospective study, it was found in 2/3 of patients with tamponade. Unfortunately, patients present-
ing with the classical “Beck’s Triad” (hypotension, distended neck veins and distant heart sounds) is 
uncommon; in once study of ultrasound-confirmed tamponade, Beck’s Triad was present in 0% of 
patients. Fortunately, there are key findings on POCUS exam that, in conjunction with the physical 
exam, can lead to rapid and accurate diagnosis of tamponade, for instance the absence of a dilated 
IVC can  exclude tamponade with 97% sensitivity.  
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16.  Chronic Hepatitis B Reactivation: Deadly, But Preventable  
 
Sarah Xie, DO, Andrea Roast, MD, FACP, Jesse Powell, MD 
 
A 51-year-old Vietnamese male with chronic hepatitis B presents with symptoms of acute hepatitis. 
2 months prior, his PCP had discontinued Tenofovir, for which he had been taking for the past dec-
ade, based on an undetectable viral load and a negative HBeAg. 1 month later, his viral load soared 
to 796 million so Tenofovir was restarted.  On admission a few days later, the patient had scleral 
icterus and jaundiced skin. He had severe transaminitis, coagulopathy, and a total bilirubin of 7.7. 
His CT showed hepatitis, but no cirrhosis.  With other etiologies ruled out, he was diagnosed with 
acute on chronic hepatitis B reactivation due to discontinuation of Tenofovir.  
 
He was discharged once his LFTs improved though his total bilirubin continued to rise.  The liver 
transplant team followed the patient post discharge and one month later, he represented with de-
compensated liver cirrhosis which progressed to fulminant hepatic failure requiring a liver transplant.  
 
An estimated 350 million people in the US live with chronic hepatitis B, though only a third are 
aware of their diagnosis.  Untreated hep B accounts for over 600,000 deaths per year from HCC 
and end stage liver disease.  There is no cure because hep B virus remains in hepatocytes by inte-
grating its DNA into our own and by turning its DNA into stable mini-chromosomes. Tenofovir AF, 
the 1st line treatment, works only by inhibiting viral replication outside the nucleus, but does not 
eradicate viral DNA (point). A negative viral load, as seen in our patient, indicates only medication 
adherence and not a cure. Only 1% of patients achieve “seroclearance of HBsAg,” constituting a 
functional cure and can discontinue medications at that point, but 99% of patient require indefinite 
treatment.  Our patient did not have labs consistent with a functional cure. Tenofovir has a black box 
warning that if discontinued, can cause hepatitis B reactivation leading to severe hepatic injury and 
even fulminant hepatic failure.  It took only one month of discontinued Tenofovir to set in motion our 
patient’s path for a liver transplant. Fortunately, he is doing well now. 
 
The take home points are that, unlike Hepatitis C, 99% of hep B patients require indefinite treatment 
to minimize the risk of premature death.  Physicians should recognize that only seroclearance of 
HBsAg suggests a functional cure.  Undetectable viral loads indicate successful treatment adher-
ence.   
 
Discontinuation of treatment can result in hepatitis B reactivation and even fulminant hepatic failure.  
From a broader perspective, clinicians need to be vigilant of undiagnosed chronic hepatitis B carri-
ers, especially in patients immigrating from countries with high prevalence or patient with high risk 
behaviors. These patients are at risk for reactivation with any immunosuppressive therapy such as 
steroids or cancer therapies. 
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17.  Necrotizing Fasciitis - Time is of the Essence  
 
Ed Kim MD PGY 3 and Jeff Sun DO PGY 3 
 
Necrotizing fasciitis (NF) is a life threatening rapidly progressive soft tissue infection that carries a 
high mortality rate. There are approximately 500-1,500 cases per year in the United States with a 
mortality rate of up to 18-20%. Without surgical intervention, the mortality rate is near 100%.  NF 
can be characterized by tissue involvement, polymicrobial or monomicrobial etiology, or site of in-
fection. The most common risk factor includes diabetes (reported in up to 60% of cases), IV drug 
use history, malnutrition, and chronic alcohol abuse. In about 50% of group A streptococcus cas-
es, there is an associated streptococcal toxic shock syndrome with multiorgan system failure. Ear-
ly recognition and prompt surgical intervention is key in improving mortality and amputation rates.  
 
We present a case of a 64-year old male with history of severe malnutrition, chronic bilateral deep 
vein thromboses on apixaban, and chronic pancytopenia who presented with rapidly worsening 
right leg pain. He was afebrile on arrival with a blood pressure of 70/40 mmHg and heart rate of 90 
bpm. Clinically he appeared cachetic and chronically ill with appreciable anasarca. His right lower 
extremity exhibited significant pitting edema with multiple hemorrhagic and flaccid bullae, areas of 
open weeping wounds with surrounding erythema, and severe tenderness to palpation. Initial labs 
showed leukopenia to 1.5k, thrombocytopenia to 107k, lactate of 3.2, procalcitonin of 152, and 
CRP of 21.9. 3-view X-ray of his right ankle showed diffuse soft tissue swelling without findings 
concerning for osteomyelitis or acute osseous abnormality. He had poor response to IV fluids and 
was found to be in septic shock. The physical exam findings and evidence of systemic involve-
ment prompted a high suspicion for necrotizing fasciitis. He was started on broad spectrum antibi-
otics and eventually needed the support of multiple pressors. Urgent surgical consultation was ob-
tained and transferred to a larger multispecialty hospital center. The patient hesitated about pro-
ceeding with surgery but ultimately decided to proceed after 24 hours when he then underwent 
debridement of his entire right leg. He ended up on three pressors and continuous renal replace-
ment therapy for two weeks. He eventually needed a tracheostomy and transferred to a long term 
acute care facility only to be readmitted two weeks later for worsening infection. He was found to 
be bacteremic with streptococcus pneumoniae and underwent a right leg above-the-knee amputa-
tion. He ultimately succumbed to his infection and died approximately 3 weeks after readmission.  
 
This case highlights the importance of both early clinical recognition and surgical intervention of 
necrotizing fasciitis due to its extremely high morbidity and mortality rate. Despite concerted efforts 
to get this patient into surgery, even a few hours of delay worsened the already poor prognosis. 
Especially as primary care physicians, prompt recognition and decisive action to get the patient 
appropriate care is crucial to improving overall outcomes. 
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18. Project Nurture: A Model for Substance Use Disorder Treatment During  
 and After Pregnancy  
 
Roxanne Thomas MD PGY 3, John Yates MD PGY 2 , Rachel Jackson MD PGY 3,  
Brenda Brischetto MD, Daniel Ruegg MD, Joshua Reagan MD 
 
Addiction during pregnancy is an increasingly common problem for American women. Sub-
stance use during pregnancy can not only lead to pregnancy and childbirth complications, but 
also has enormous social costs that affect women, children and families in Portland and across 
the country. Project Nurture has provided a successful model for Substance Use Disorder treat-
ment during pregnancy, combining Medication Assistance Treatment, prenatal care, drug and 
alcohol counseling, peer mentoring, and social services that improve outcomes for women suf-
fering from addiction, as well as their children. Housed within a Family Medicine Residency, 
Project Nurture has also provided doctors in training with valuable experience caring for preg-
nant women and babies affected by Substance Use Disorders.   
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19.  Add Sweet’s Syndrome to your dermatologic differential  
 
Dr. Elizabeth Deyo, Dr. Mike Waddick 
 
Context:  
Sweet’s Syndrome, an uncommon acute painful inflammatory rash, can be easily misdiagnosed. 
Early recognition and treatment can speed clinical recovery for patients with this difficult condi-
tion. 
 
Objective:  
Here we describe an interesting case report of Sweet’s Syndrome in one of our patients in order 
to help providers remember this diagnosis on their dermatologic differential diagnosis.  
 
Case report synopsis:  
Our 44 year old male HIV positive patient with type 2 diabetes mellitus presents with athralgias, 
chills, malaise and a plaque-like rash on the back of his neck, head and right wrist.  Course: Lab 
work-up with blood culture, crp, cbc, cmp, HIV viral load, RPR, and biopsy were performed. The 
biopsy confirmed neutrophilic dermatosis consistent with Sweet’s Syndrome. The patient was 
started on treatment after biopsy results returned. The patient had rapid improvement with treat-
ment. 
 
Treatment: Prednisone 30mg daily for 7 days, then tapered over 5 weeks.  
 
Conclusion:  
Sweet’s Syndrome, an acute febrile neutrophilic dermatosis, is an uncommon inflammatory skin 
condition characterized by the abrupt onset of painful erythematous papules, plaques or nodules 
and systemic symptoms.  The disease is classified into classical (idiopathic), malignancy-
associated and drug-induced Sweet’s Syndrome.  While uncommon, primary care physicians 
should be familiar with the clinical presentation, diagnosis and initial management of this disease; 
and add it to their differential diagnosis when faced with acute painful rashes as described 
above. Key points include the diagnostic criteria, clinical appearance, and initial treatment of 
Sweet’s Syndrome.   
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20.  The Dose Makes the Poison, or does it? Judicious Management of TCA Intoxication. 
 
Sean Brachvogel, MD PGY1, MPH Resident; Justin Osborn, MD; Tanya Page, MD  
 
Context/background:  
Tricyclic antidepressants (TCAs) have been mostly supplanted by SSRIs in the treatment of depres-
sion, however they remain a mainstay of chronic pain management (Meloy). Untreated suicide at-
tempts with a TCAs carry a 70% fatality rate, which drops dramatically to 3% with hospitalization 
(https://emedicine.medscape.com/article/819204-overview#a6). As such, maintaining healthcare 
provider recognition and management of TCA toxicity is of lifesaving importance.  
 
Objective:  
Here we describe a case report in which alcohol ingestion masked the severity of an accidental 
TCA overdose, and we reflect on a common diagnostic approach. 
 
Case Report:  
Our discussion begins with a 68-year-old Caucasian female with a history of COPD, diverticulitis, 
HLD, HTN, and chronic pain who presents with 80 minutes of altered mental status after consuming 
alcohol and her regularly prescribed amitriptyline. Her EKG demonstrated QRS widening and her 
serum alcohol level was 217. She was diagnosed with TCA overdose and alcohol intoxication and 
was treated with a sodium bicarbonate drip. Management of her TCA intoxication was clouded by a 
background of significant alcohol intoxication, and an amitriptyline and nortriptyline levels were col-
lected to elucidate the severity of the TCA overdose. After eight hours of bicarbonate infusion her 
QRS narrowed and her condition stabilized.  
 
Conclusions:  
TCA therapy is common and TCA overdose is both especially dangerous and treatable. In our case 
collecting amitriptyline and nortriptyline levels did not aid in our diagnosis or treatment. We con-
clude that EKGs are the superlative diagnostic modality when evaluating suspected TCA overdos-
es. 
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21. Death Files: a case of pancreatitis                                                                                          
 
Christelle Serra Van Brunt PGY3 
 
Context/Background:  
Case report of a 30yo male who presented to the ED with his second episode of pancreatitis 
after binge drinking over the weekend.  
 
Objective:  
Identify early prognosis markers and review common complications of pancreatitis 
 
Case Report synopsis:  
30yo male presented to the ER after acute onset of epigastric pain radiating to his back, nau-
sea, vomiting. Patient reported binge drinking over the weekend but denied any drinks for the 
last 4 days. On presentation, patient had a lipase of 2600 and a CT abdomen with considerable 
edema surrounding the pancreas. Patient decompensated abruptly 6hours after presentation, 
developing lactic acidosis unresponsive to bicarbonate drip, and eventually renal failure, ab-
dominal compartment syndrome, and finally fulminant liver failure leading to death despite hero-
ic measures.  
 
Conclusions:  
Pancreatitis severity needs to be assessed at presentation. Current scoring systems are imper-
fect, using data over the first 48hours to assess severity. However clinicians can combine the 
APACHE II, or Ranson’s criteria with imaging, CRP and clinical judgement to assess, triage ap-
propriately, and treat severe pancreatitis cases. 
 
Link to Poster 
22.  Miliary Tuberculosis: A Case Report 
 
Jamie Skreen, DO PGY3 ; Tanya Page, MD  
 
Context/background:  
Miliary tuberculosis is a condition that is fatal if not diagnosed and can present in the outpatient 
setting with vague symptoms that resemble a viral illness, therefore, can be easily missed. 
Recognition of this disease as a differential is important in the primary care setting, especially 
when caring for immigrant and International patient populations. 
 
Case Description:  
A previously healthy 35 yo female from Vietnam whom presented initially to the ER for head-
ache and fever for the past 2 weeks. She was diagnosed with acute viral syndrome given her 
symptoms, normal labs, and head CT, and discharged home. A few days later, she presented 
to an urgent care because she began having blurry vision, nausea, vomiting, lethargy and had 
incoherent speech. She did not have any URI symptoms, cough or hemoptysis. At the urgent 
care, she was noted to have some neck stiffness, fatigue, unsteady gait, and fever to 103F. 
They had her return to the emergency room for further workup. In the ED, she had an LP that 
revealed lymphocytic-predominant pleiocytosis, elevated protein, and low glucose. ID was con-
sulted, from LP alone, differential included early viral meningitis vs bacterial (pyogenic vs AFB 
vs other atypical pathogens such as Listeria, Brucella, Syphilis) vs Cryptococcus. She was 
started on CTX, vancomycin, and acyclovir while workup was pending. She had a CXR to look 
for evidence of prior TB, which resulted in ”diffuse pulmonary nodularity.” Differential includ-
ed respiratory bronchiolitis, miliary tuberculosis and other fungal infections, hypersensitivity 
pneumonitis and viral infection. After CXR, she was placed on airborne precautions and in a 
reverse flow room given possibility of TB. Because she had neurological symptoms, she re-
ceived a brain MRI, which showed ”small ring-enhancing lesions in the left frontal cortex and 
right frontal cortex.” The following day, CSF resulted was positive for TB by PCR, confirming 
the diagnosis. Treatment with rifampin, isoniazid, pyrazinamide, ethambutol (“RIPE”) was 
immediately started. Contacted by the county health department and they stated that even 
though there was a diagnosis, a sputum sample was needed to determine level of 
contagiousness. She was unable to produce sputum, even with induction (she had no cough), 
therefore she had bronchoalveolar lavage for sputum culture, resulted in 3+ (moderate) 
Mycobacterium tuberculosis. She continued the RIPE regimen and was discharged from the 
hospital the following day.  
 
Discussion:   
Although miliary TB is a rare form of TB (2% of TB cases), when missed it can be fatal, as mor-
tality rate is between 15 to 30%. One of the main causes for high mortality includes late detec-
tion of disease caused by non-specific symptoms. Recognition of this disease as a differential 
is important in the primary care setting and when caring for international patient populations.  
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23.  Unpainfully Sweet 
 
Khoi Nguyen, DO, Alex Schafir, MD 
 
Introduction: Sweet's syndrome (ss), or acute febrile neutrophilic dermatosis, is characterized by 
sudden onset of fever, leukocytosis and erythematous plaques or nodules infiltrated by neutrophils. 
There are three main clinical settings in which Sweet's syndrome has been described: The diagno-
sis of Sweet’s syndrome often has a temporal association with the discovery or relapse of cancer as 
reported in this case. 
Case Report: A 64-year-old woman with recurrent breast cancer on targeted and hormonal therapy 
presented to the ED with acute onset of fever and diffuse non-tender body rash. Vitals suggested 
sepsis and she was treated with broad spectrum antibiotics. A chest xray, viral panel, blood cul-
tures, echocardiogram and urinalysis were unrevealing. Erythrocyte sedimentation rate and C-
reactive protein were elevated. There were 90% neutrophils. When her erythematous plaques be-
came vesicular, she was treated with IV Acyclovir for possible disseminated zoster. This was dis-
continued when biopsy for HSV/HZV returned negative. Skin biopsy, however, showed dense neu-
trophilic infiltration consistent with Sweet Syndrome. Treatment with prednisone resulted in rapid 
clinical improvement. 
Discussion: Historically, the diagnosis of SS requires the presence of painful erythematous lesions 
(both Major Criteria and two of four Minor Criteria). The absence of pain and tenderness in this pa-
tient made the diagnosis challenging. After extensive evaluation to rule out infectious etiology, it 
was revealed through skin biopsy that her syndrome was more consistent with Sweet Syndrome 
despite having non-tender lesions. Given her recent recurrence of breast cancer, it was thought that 
her SS was more consistent with Malignancy-Associated SS (MASS) subtype. MASS is most com-
monly associated with hematological malignancies such as AML, but also occurs coincident with 
solid tumors, such as carcinomas of GU organs, breast, and GI tract. In patients with a previous his-
tory of cancer, the diagnosis of SS usually heralds the onset of recurrence. Sweet syndrome may 
precede, follow, or appear concurrently with a malignancy. This patient was found to have a recur-
rence of breast cancer in the form of bone metastases two months prior to admission. In summary, 
this case demonstrates an atypical painless presentation of SS and how evaluation for malignancy 
is indicated for patients with SS, particularly when there is an absence of other explanations such 
as recent infection, inflammatory disease or drug exposure. Treatment : Prednisone 0.5mg to 1mg/
kgper day. Symptoms usually improve within 48 hours and skin lesions resolves within 1 to 2 
weeks. Steroid is then taper over course of 4 to 6 weeks. 
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24.   Struck By Lightning Twice 
 
Bao-Ngoc Nguyen, MD, Emily Hitchock, MD 
 
INTRODUCTION: ANCA-associated vasculitides (AAV) refer to a group of disorders causing inflam-
mation of small vessels which include granulomatosis with polyangiitis (GPA), microscopic polyan-
giitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss). Here I pre-
sent a case of MPA vasculitis in a patient with alpha-1-antitrypsin (AAT) deficiency, and describe a 
proposed causal link between these two rare disease processes. 
 
CASE REPORT: • 43-year-old man with history of newly-diagnosed AAT deficiency liver disease. • 
Chief complaint of subacute shortness of breath associated with hemoptysis and fever for 5 months. 
• Symptoms had been progressively worsening despite multiple courses of antibiotics and inhalers. 
• Pulmonary CT angiogram (CTPA) was negative for pulmonary embolism but showed “multifocal 
pulmonary infiltrates for which pneumonia and septic emboli could not be excluded”. • Infectious 
workup negative. • Positive myeloperoxidase (MPO) antibodies and findings on thoracoscopic lung 
biopsy most consistent with MPA. • Managed with steroids and rituximab. 
 
DISCUSSION: • AAT is an acute-phase protein that inhibits the serine proteases of inflammatory 
cells, including proteinase 3 (PR3), to protect tissues from damage. •Mutations in the AAT-encoding 
gene SERPINA1 result in a structural change in AAT that inhibits its release into the bloodstream, 
leading to higher levels of proteases in the blood that can then cause excessive tissue damage. 
•Because increased levels of PR3 is a major component in the pathogenesis of ANCA vasculitis, a 
causal link between AAT deficiency and ANCA vasculitis has been proposed. There are many case 
reports describing this association, but the level of detail is variable based on the tests available at 
the time of the report. •Even though ANCA vasculitis is relatively rare, it is worth considering and 
pushed closer to the top of the differential list when a concurrent history of AAT deficiency is pre-
sent. 
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25.  Purpura Fulminans due to MSSA Toxic Shock Syndrome 
 
Leah Grant, MD, Rachel Plotinsky, MD 
 
Introduction: Purpurafulminansis a rare and serious complication of anacute infectious process, 
characterized by large purpuric skin lesions, fever, hypotension, and DIC. The most common infec-
tious cause of purpurafulminansismeningococcal disease, though few case reports in the iterature 
describe Staph aureus as a causative organism. 
 
Case Report: •A 53 year-old woman with a history of heart blocks/pacemaker placement in 2002 
presented to the ED with nausea, vomiting, fevers, chills, diffuse muscle pain and asynco-
palepisode. •She was found to have multi-organ dysfunction on labs, including AKI and thrombocy-
topenia.On hospital day 2, she developed acrocyanosis. She became febrile & hypotensive requir-
ing transfer to the ICU for vasopressor support. Blood cultures were obtained. She was started on 
broad-spectrum antibiotic therapy . •Because of the patient’s thrombocytopenia and overall critical 
illness, the differential diagnosis included TTP, DIC, HUS, drug-induced hemolytic anemia, or a rare 
disorder called catastrophic antiphospholipid antibody syndrome (CAPS). •She was treated empiri-
cally for CAPS with plasma exchange, heparin, and steroids. •Blood cultures were positive for 
methicillin-sensitive Staphaureus, and antibodies for CAPS were negative. •Antibiotic therapy was 
narrowed to Cefazolin, and her infected pacemaker was extracted. •She required bilateral below-the
-knee amputations as well as multiple finger amputations due to necrosis. •Most likely diagnosis is 
purpurafulminans from MSSA toxic shock syndrome. 
 
Discussion: • In acutely ill patients with skin findings described in this case as well as multi-organ 
dysfunction, there are several life-threatening diagnoses which must be recognized and treated 
promptly . •Given the 50% risk of mortality even with prompt initiation of therapy for CAPS, we did 
not delay in starting this patient on plasma exchange . •In purpura fulminans, the clotting cascade is 
disrupted by bacterial endotoxins and inflammatory cytokines, leading to a procoagulant and antico-
agulant state, which in turn leads to intravascular thrombosis and hemorrhagic infarction of the 
skin . • A report of 5 cases of purpurafulminans caused by MSSA TSS was published in the journal 
Clinical Infectious Diseases in 2005, and the isolated strains of MSSA were noted to produce higher
-than-expected levels of endotoxins normally associated with TSS. •Treatment of purpurafulminans-
from MSSA TSS is antibiotic therapy. •It remains a rare and serious complication of acute infection 
which providers should keep on their differential of life-threatening illnesses associated with throm-
bocytopenia and purpuric skin lesions. 
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26.  Pulmonary Nocardiosis in an Immunocompetent Host  
 
Leah Grant, MD, Laura Loetscher, MD, Jennifer Marfori, MD 
 
Introduction: • Nocardia is known to cause severe pulmonary or disseminated infection in immuno-
compromised patients, but can cause infection in immunocompetent patients. Providers should con-
sider Nocardiosis in immunocompetent patients with prolonged and unexplained respiratory failure. 
• The preferred therapy for pulmonary Nocardiosis is a sulfa antibiotic for 3-6 months. Toxicity from 
prolonged use of alternative agents presents a therapeutic challenge in those with sulfa allergy. 
 
Case Report: • An 85 year-old woman with a history of paroxysmal atrial fibrillation and heart failure 
with preserved EF presented to her primary care provider with 1 week of cough and progressive 
dyspnea. Chest x-ray (CXR) was normal, and echocardiogram demonstrated known HFpEF without 
new abnormalities. • Two months later, she presented to the hospital with progressive dyspnea, 
chest tightness, and was found to be hypoxic. CXR on admission showed bilateral consolidations as 
well as mediastinal and hilar adenopathy. She was treated with ceftriaxone & azithromycin for pre-
sumed community-acquired pneumonia (CAP). • Due to treatment failure, a CT Chest was obtained 
and showed a mass-like consolidation in the right middle lobe; she was discharged with a several-
week prednisone taper for treatment of presumed cryptogenic organizing pneumonia. • Two weeks 
later, she returned for worsening dyspnea, chest pressure, malaise, and hypoxia. She was again 
treated for CAP and discharged. • One month later, she was admitted for similar symptoms, and a 
CT-guided lung biopsy showed several small clusters of long Gram-positive bacteria consistent with 
Nocardia spp. Tissue culture was positive for Nocardia cyriacigeorgica complex. • The patient was 
offered a challenge of her sulfa allergy (reported as a rash), but refused. She was started on linezol-
id in anticipation of a 6 month course of therapy. • Her hospitalization was complicated by cardiac & 
renal dysfunction. Due to severely impaired quality of life, the patient elected for hospice care and 
died approximately 2 weeks after discharge. 
 
Discussion: • Nocardiosis most commonly presents as a pulmonary infection as inhalation is the 
primary route of exposure. • More than half of all reported Nocardiosis cases are associated with 
preexisting immunocompromise such as organ transplantation, AIDS, diabetes, chronic granuloma-
tous disease and alcoholism. More recently published case reports depict Nocardia infections in im-
munocompetent patients with a prior history of lung disease, such as chronic obstructive pulmonary 
disease, allergic bronchopulmonary aspergillosis, and bronchiectasis. • Our patient was neither im-
munocompromised, nor had a prior history of lung disease, though was an elderly person. Im-
munosenescenceis associated with decline in innate as well as T-cell immunity, which may have 
imparted risk to our patient. • The mainstay for treatment of Nocardia infections is trimethoprim-
sulfamethoxazole (TMP-SMX). Alternative oral agents include minocycline, amoxicillin-clavulanate, 
and linezolid. • Had our patient not chosen the route of hospice care, close monitoring for linezolid 
toxicity would have been necessary with possible TMP-SMX re-challenge for long term therapy. 
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27.  Not Just Kids—A case of Adult IgA Vasculitis 
 
Heidi Reich, MD, Jeff Youker, MD 
 
INTRODUCTION: IgA vasculitis, formerly known as HenlochSchonleinPurpura, is generally recog-
nized as the most common form of systemic vasculitis in children, with 90% of cases occurring in 
the pediatric age group. However, the remaining 10% are noted in adult populations, and often has 
poorer long term outcomes if not identified and treated quickly. IgAV is commonly associated with 
streptococcal infections, although additional triggers such as drug ingestions, insect bites, and vac-
cinations have been described. Symptoms can include palpable purpura, acute abdominal pain, ar-
thralgias, and hematuria. Recognizing the constellation of signs and symptoms is key for expediting 
appropriate therapy, which may reduce long term renal damage. 
 
CASE REPORT: A 27-year-old man with a history of asthma presented to the ED for maculopapu-
lar rash, polyarthralgias, and myopathy. Found to be hypertensive (160s/100s) and tachycardic 
Creatinine 1.3, ESR 13, and CRP >80 History was significant for an upper respiratory ill-
ness 10 days prior, camping trip 5 days prior with ingestion of several drugs including cocaine, 
MDMA, marijuana and psychogenic mushrooms. He was admitted overnight for rheumatologic and 
infectious disease workup, but discharged the following day with plan for outpatient follow up. Two 
days later, he again presented to the ED with acute abdominal pain and nausea with multiple epi-
sodes of vomiting, and was readmitted. Persistently hypertensive (160s/100s) Worsened pur-
puric rash Nonpitting edema in upper and lower extremities Creatinine 1.2, normal CBC, ASO 
titer elevated (957) CT abdomen showed small bowel edema, and EGD/colonoscopy were incon-
clusive His collective symptoms were reviewed and included the following: Palpable purpura with-
out thrombocytopenia or coagulopathy Arthralgias Abdominal pain IgAV was hypothesized and 
skin/renal biopsies were obtained. Skin biopsy: “leukocytoclastic vasculitis with granular IgA dep-
osition in superficial vascular walls” Renal biopsy: “positive mesangial immunofluorescence for 
IgA” Based on these findings in conjunction with his symptoms and lab findings, he was started on a 
long steroid taper with plan for close outpatient follow-up. 
 
DISCUSSION: IgA vasculitis can affect many organ systems including integumentary, GI, and re-
nal. Although it is most common in children age 5-9, it can affect adults and requires prompt recog-
nition to facilitate appropriate therapy. The classic tetrad of symptoms includes: Palpable purpura 
without thrombocytopenia and/or coagulopathy Arthralgias Abdominal pain Renal disease 
These symptoms often present in a predictable order, with purpura noted 4 days prior to other 
symptoms. Our patient required careful blood pressure management due to his renal involvement 
(started on ACEI), and steroids were initiated. At time of discharge, his renal function and rash were 
improving, and abdominal pain had resolved. Although full renal recovery is common in up to 89% 
of patients, long term renal impairment may occur. Close monitoring is imperative to minimize fur-
ther renal damage. 
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28.   Lemierre’s Syndrome 
 
Jennifer Nguyen, MD, Tom Chau, MD 
 
INTRODUCTION: Lemierre’s syndrome is a rare and potentially fatal complication of acute pharyn-
gitis most commonly seen in healthy, young adults who present with neck pain and persistent, high-
grade fever. It is caused by anaerobic gram-negative organisms, most often Fusobacteriumnec-
rophorum, spreading into the deep spaces of the neck. This leads to septic thrombophlebitis of the 
internal jugular vein (IJ) with septic emboli, most frequently to the lungs. 
 
CASE REPORT: A healthy 18-year-old woman presented to the hospital with five days of fever, ri-
gors, sore throat, and left neck pain. She appeared relatively non-toxic but was febrile to 105.6℉ 
and in septic shock. Her source of infection was initially unclear. Her work up included: • Normal CT 
neck with contrast and urinalysis. • CT abdomen and pelvis coincidentally showed multiple septic 
emboli within the lungs. • Blood cultures grew F.necrophorum. Re-evaluation of her admission neck 
CT revealed a modest filling defect in her left IJ. With her constellation of sore throat, left IJ throm-
bophlebitis, septic pulmonary emboli, and F.necrophorumbacteremia, her presentation was felt to 
represent Lemierre’s syndrome. She was initially treated with piperacillin/tazobactam and then tran-
sitioned to IV penicillin G with rapid clinical improvement. She was discharged home to continue two 
more weeks of IV penicillin G followed by two weeks of oral amoxicillin/clavulanate. 
 
DISCUSSION: What constitutes Lemierre’ssyndrome is controversial however the “classic” Lem-
ierre’ssyndrome case consists of: • Healthy, young adult with pharyngitis. • Within 4-5 days, devel-
ops worsening neck pain, sore throat, high fevers, and rigors. • F.necrophorumbacteremia with jug-
ular venous thrombophlebitis and disseminated septic emboli. • Most common sites for septic em-
boli include the lungs, joints, soft tissue, and abdomen. In retrospect, my patient’s clinical presenta-
tion was typical for Lemierre’s syndrome, even before her blood cultures resulted with 
F.necrophorum. Although a rare disease with an incidence of approximately one per million persons 
per year, there has been a resurgence of reported cases since the 1990’s which some people hy-
pothesize may in part be due to clinicians limiting the use of antibiotics to treat pharyngitis. Addition-
ally, studies have found that F.necrophorumis a more common cause of acute pharyngitis than 
Group A Streptococcus. However, unlike Group A Streptococcus, F.necrophorum infections cannot 
be treated with macrolides and treatment often involves a prolonged course of penicillin antibiotic 
including parenteral therapy. As such, my patient’s case demonstrates the importance for all intern-
ists to be aware of the classic symptoms of Lemierre’s syndrome, a complication of acute pharyngi-
tis, as delay in diagnosis and treatment could potentially result in fatal consequences. 
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29.  Catastrophic Antiphospholipid  Syndrome 
 
Gabriel Hocum, DO,  Jeff Youker, MD 
 
INTRODUCTION: Catastrophic Antiphospholipid Syndrome (CAPS) is a rare and extreme manifes-
tation of Antiphospholipid Syndrome (APS) that features widespread thrombotic disease affecting 
multiple small vessels in a short time frame. CAPS affects only 0.8% of APS patients, but when it 
occurs it is has a mortality rate of approximately 50%. 
 
CASE REPORT: A 50 year old female with SLE and APS presented with 1 month of cough and fa-
tigue and 2 days of severe confusion after missing doses of rivaroxaban. In the ED she was intubat-
ed for airway protection and transferred to the ICU. Her evaluation revealed multi-organ failure with 
extensive subacute brain infarcts, NSTEMI, severe heart failure, acute kidney injury, and acute on 
chronic anemia and thrombocytopenia. Her brain lesions were randomly distributed and could not 
be explained by a typical cardio emobolic phenomenon or global hypo-perfusion. Lab work revealed 
decreased C3 and C4, and increased anticardiolipin and anti-B2-glycoprotein antibodies. She was 
diagnosed with probable CAPS based on clinical criteria, and treated with high dose steroids, anti-
coagulation and IVIG. Her acuity prevented histopathologic confirmation of small vessel occlusion. 
Despite some signs of clinical improvement and successful prevention of further thrombotic events, 
she had sustained extensive irreversible neurologic damage and was transitioned to comfort care. 
 
DISCUSSION: Most of our understanding of this condition comes from retrospective analyses of 
patients in the “CAPS Registry”, which in 2016 included about 500 patients. It is more common in 
women, and the average age of onset is 38. 60% of these patients had an underlying primary diag-
nosis of APS; 30% had an associated SLE diagnosis; 65% of cases had an identifiable antecedent, 
most commonly, infection. Diagnostic Criteria: 1. Involvement of three or more organs, systems, 
and/or tissues 2. Development of manifestations simultaneously or in less than a week 3. Presence 
of antiphospholipid antibodies 4. Histopathologic evidence of small vessel occlusion in at least one 
organ or tissue Treatment: 1. Treatment of the inciting factor if one is identifiable (e.g. antibiotics for 
bacterial infection) 2. Anticoagulation, usually with heparin 3. High dose intravenous steroids 4. 
Plasma exchange and/or IVIG 5. Other considerations: cyclophosphamide, rituximab, eculizumab 
This case highlights the severity of the CAPS disease process, and the importance of early recogni-
tion and aggressive management. The primary prognostic factor for this patient, however, was not 
prompt diagnosis or treatment, but the extent of irreversible damage at the time of presentation. 
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30.  Accidental Botulism Poisoning:  A Case of Pickled Herring 
        
Garrett Spencer, MD, Greg Flick, MD 
 
INTRODUCTION:  Botulism is a rare cause of neuromuscular weakness that presents a diagnostic 
challenge in the face of respiratory collapse. Pupil and bulbar paralysis aid prompt recognition and 
treatment, as clinical confirmation can be time intensive and limited by sample integrity. Early treat-
ment can halt paralysis and prevent ICU and ventilator days. 
 
CASE DESCRIPTION: A 74-year-old male with hypertension and DVT presented with acute weak-
ness and respiratory failure after three days of cough and diarrhea. Upon ICU admission for me-
chanical ventilation, we discovered sluggish pupils, mild ptosis, and proximal muscle weakness. 
Symptoms then progressed to unresponsive pupils, complete ptosis, and complete paralysis. While 
we suspected a neuromuscular cause, no single cause was identified despite extensive workup 
and neurology consultation. Our differential was narrowed after electromyogram (EMG) demon-
strated a pre-synaptic defect, indicating either Lambert Eaton or Botulism as culprits. Empiric treat-
ment with botulism anti-toxin resulted in clinical improvement of ptosis and proximal weakness. 
While ventilated, he wrote of recent pickeled herring ingestion, possibly left unrefrigerated for a 
week. He ultimately received tracheostomy and transfer to long-term assisted care, and at dis-
charge stool and serum testing for botulism toxin was still pending. While state-run testing finally 
returned negative, his illness was ultimately attributed to accidental botulism poisoning. 
 
DATA: 
Differential and Workup 
Myasthenia Gravis • CT Chest: no mediastinal/thymic mass (thymoma) • Acetylcholine Receptor 
Ab: negative • Striated Muscle and Titin Ab: negative Lambert Eaton • Pre-synaptic defect on EMG: 
low motor amplitudes that increased with sustained exercise • Voltage Gated Calcium Chanel Ab: 
negative • CT Chest: no nodules or masses (paraneoplastic SCLC in 50%) Demyelinating Polyneu-
ropathy • LP: Glucose 76, protein 53, WBC 0, RBC 0, lymphocytes 67% • CSF: Ganglioside GM1 
Ab negative Botulism • Stool: rejected, poor specimen quality • Serum: small sample size, Endopep
-MS assay negative Central and Infectious • MRI brain and C-spine normal Infectious • Treponemal 
Ab negative • Lyme Ab negative 
Botulism Key Features 
Exam • Respiratory collapse • Proximal then distal paralysis, rapid progression • Preserved sensa-
tion, reflexes • Bulbar Paralysis with pupil involvement, nystagmus Workup • Botulism Neurotoxin 
(BoNT) of fluid, serum samples • Mouse Bioassay Treatment • Botulism equine anti-toxin, early ad-
ministration can reduce ventilator and ICU days 
 
RESULTS / DISCUSSION: Yearly US incidence of botulism is 100 cases, and early treatment with 
equine anti-toxin reduces mortality and ventilation time1. Timely diagnosis is challenging as respir-
atory collapse overshadows subtle pupil and bulbar paralysis unique to botulism2. Lab diagnosis 
with Endopep-MS assay is not FDA approved and can be falsely negative with small samples3 
while verified sacrificial mouse bioassays are rarely used2. Early suspicion should prompt anti-toxin 
treatment and discussion with the CDC’s botulism consultation service, who will supply anti-toxin 
and provide assistance with workup in conjunction with state health laboratories.  
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31.  Ceftriaxone-Induced Immune Hemolytic Anemia from Treatment of Post –Treatment 
Lyme Disease Syndrome 
 
Jillian Catral, MD, Emily Hitchcock, MD 
 
INTRODUCTION: Drug-induced immune hemolytic anemia (DIIHA) is a rare though likely underreported en-
titythat is associated with significant morbidity and mortality. • Ceftriaxone is a commonly used antibiotics 
with a well-documented association with DIIHA. The mechanism is a drug-dependent antibody, immune-
complex mediated reaction which can be severe, leading to organ failure, shock, and even death. • While the 
majority of cases are in children, a recent literature review had one-third of cases being adults, with up to 30-
40% mortality in all ages. • This case describes an adult patient treated for the controversial diagnosis of post
-treatment Lyme disease syndrome (PTLDS) which resulted in ceftriaxone-induced immune hemolytic ane-
mia (CIIHA). 
 
CASE REPORT: The patient is a 72-year-old active female from Minnesota with self-reported history of dis-
seminated Lyme disease and Babesiosis diagnosed in the 1980s, Graves’ disease, hypertension, and fi-
bromyalgia. • She presented with 3-4 weeks of progressive fatigue to being walker-dependent and mild cog-
nitive impairment in setting of recently diagnosed normocytic anemia since starting 3x-weekly ceftriaxone-
pulse therapy for PTLDS recommended by her PCP in California and prescribed by her local naturopathic 
doctor. 
 
Evaluation: CBC: WBC 6.4, Hgb 9.4 (baseline ~14) with MCV 88, Plt 288 CMP: Total bilirubin 1.3 (from 1.8 
two days prior to admission) Direct Coombs test: positive for IgG+ complement, IgG Peripheral smear: sphe-
rocytes, schistocytes 
Haptoglobin: 
LDH: 343 
Reticulocyte index: 7.37 % retic: 16.7 Absolute reticcount: 518 
Ferritin 245, Fe 65 TIBC 408, %sat: 16 
TSH 0.30, FT4 1.57 
 
• Her ceftriaxone had already been discontinued 1 week prior to admission due to concern for DIIHA, which 
was consistent with her hospital workup. She was discharged home in fair but stable condition, and her ane-
mia, energy, and cognition continued to improve in the weeks-months following. 
 
DISCUSSION: This patient was determined to have a subacute immune-mediated hemolytic anemia with 
symptoms that correlated temporally with her ceftriaxone infusions. • DIIHA is a rare but potentially fatal enti-
ty with incidence of 1/1,000,000. Ceftriaxone (among other 2nd/3rdgeneration cephalosporins) and piperacil-
lin, are commonly used antibiotics which have been associated with DIIHA. DIIHA has several mechanisms 
(see Figure 2). In the case of ceftriaxone, CIIHA is an immune complex-mediated reaction due to drug-
dependent anti-ceftriaxone antibodies (acAb). • Other features found in CIIHA patients include acute renal 
failure, hepatitis, and DIC (see Figure 3). One study suggested an increased risk of CIIHA in patients with 
underlying conditions such as sickle cell disease and HIV, or previous exposure to ceftriaxone such as in this 
patient. • Treatment is withdrawing the offending drug and supportive measures as needed such as with 
blood transfusions. Some patients have been treated with plasmapheresis, corticosteroids, and IVIG. • 2016 
Infectious Disease Society of America (IDSA) State Policy Primer on PTLDS: “The potential benefit of long-
term use of antibiotics for the treatment of Lyme disease has been examined and found ineffective in multiple 
well-done clinical trials. … Long-term antibiotic therapy can cause many serious health consequences includ-
ing protracted and intractable diarrhea, severe colitis, antibiotic resistance, allergic reactions, bloodstream 
infections and clots from intravenous catheters, and even death, without any scientifically-founded prospect 
of benefit.” 
 
CONCLUSION: Early recognition of DIIHA (which can cause severe, sometimes fatal, reactions) and cessa-
tion of the causative agent is important to reduce the high morbidity and mortality associated with these pa-
tients. •The role of antibiotics in (and even the diagnosis of) PTLDS is contended. Potential for serious ad-
verse effects such as DIIHA among others should be considered prior to initiating antibiotics for PTLDS. 
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32.   Swimming Through Lake Placid:  a Major Headache 
 
Elizabeth Severson, DO, Claudia Leonard, MD 
 
Introduction: Leptospirosis is caused by Leptospira species, a spirochete bacterium that affects 
animals and humans. The disease can range from mild flu-like illness to multi-organ failure. While 
likely underreported, the incidence according to the World Health Organization can range from 0.1 
to 10 per 100,000 depending on climate Leptospirosis is commonly associated with occupational or 
recreational exposures 
 
Case Report: A 43 year-old previously healthy man presented with two weeks of myalgias, fevers, 
neck pain and throbbing headache. The patient competed in an Iron Man event in upstate New York 
one month prior to presentation. Initial investigation demonstrated a mild anemia, elevated ami-
notransferases and negative head CT. Lumbar puncture revealed a cerebrospinal fluid (CSF) pleo-
cytosis, normal glucose, mildly elevated protein, and negative gram stain, consistent with aseptic 
meningitis. The patient was started on acyclovir. Given his recreational risk factor for Leptospirosis 
in the setting of characteristic clinical features, we added doxycycline on admission Acyclovir was 
discontinued after negative HSV PCR. Within 24 hours, he improved significantly and was dis-
charged with a course of doxycycline. Subsequently, all elements of the infectious evaluation re-
turned negative except a positive Leptospirosis Ab. The patient’s symptoms and transaminitis fully 
resolved. 
 
Discussion: Leptospirosis is among the most common zoonotic infections worldwide, however in 
the United States only about 100-150 cases are reported annually, mostly in Hawaii and Puerto Ri-
co. The organism infects humans through contact with urine of infected rodents, dogs, and livestock 
or urine-contaminated environments. Patient’s commonly present with: • Fevers, myalgias, and 
headaches after an incubation time of 2 to 26 days • Other findings can include cough, arthralgias, 
nausea and vomiting, abdominal pain, and rash • About 40% of people have elevated aminotrans-
ferases, and 50-85% have aseptic meningitis • Severe cases can progress to jaundice, renal failure, 
pulmonary hemorrhage, myocarditis, rhabdomyolysis, and ARDS Leptospirosis is associated with a 
variety of risk factors, including occupational exposures and recreational activities. Large outbreaks 
are usually associated with recent rainfall or flooding. The bacteria can invade through skin abra-
sions and conjunctiva, or by swallowing contaminated water. The relationship between the risk of 
outdoor water sports and Leptospirosis infection is well described in the literature, with outbreaks 
around the world, including in Illinois (1998) and Florida (2005). Coincidentally, there had been sig-
nificant recent rainfall with run-off into Lake Placid, the location of this patients Iron Man competi-
tion. Our patient’s CSF analysis was consistent with aseptic meningitis, but the time course was 
longer than expected for viral meningitis. Although rare in the United States, clinicians should con-
sider leptospirosis in patients with aseptic meningitis, elevated aminotransferases, and potential ex-
posure history. 
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33.  Healthcare Leadership Academy:  Resident And Faculty Interprofessional Training  
In Leadership, Population Health, and Patient Safety 
 
Samreen Kahn, MBBS, Victoria Costales, MD, MPH 
 
Background:   
In the era of accountable care, physicians are called upon to lead multidisciplinary teams for effec-
tive clinical practice and population health redesign. Physician leadership training programs are of-
ten siloed and rarely involve non-physician professionals. To address this gap, we developed the 
Healthcare Leadership Academy (HLA), an interprofessional leadership training for resident physi-
cians and faculty. In this study, we present an evaluation of the first 3 HLA cohorts. 
 
Methods:   
A 10-item post-program survey was administered to all HLA participants, evaluating program satis-
faction/value and components. To further assess the impact on graduate medical education, we 
conducted focus group interviews with resident physicians to gauge the value of the HLA training 
and gather lessons learned for future program enhancements. 
 
Results:   
In 2016-2018, 3 cohorts from various hospital departments participated in 15 HLA sessions, cover-
ing topics in leadership, management, population health, and patient safety.  Culminating group 
work addressed a quality improvement project of significance to our patient population. Thirty of 50 
participants completed the post-program survey (response rate: 60%). Most (97%) “strongly 
agreed” or “agreed” that the HLA had a positive impact on their personal and professional develop-
ment. Five residents were interviewed. The themes that emerged included “learning from the 
‘other’”, “quality improvement/working in a team”, “improved communication”, and “areas of im-
provement”. 
 
Conclusion:   
An interprofessional leadership training program addressing leadership, management, population 
health and patient safety is a valuable personal and professional development experience for resi-
dents, faculty, and hospital staff. Incorporating a population health project enriches team-based 
care while also promoting systems-based improvements that help promote better patient outcomes. 
 
Public Health Implications:   
Interprofessional leadership practice and education are essential as we advance the quadruple aim 
of improving the health of populations, enhancing patient experience, reducing cost, and improving 
the work-life of healthcare providers. 
34.   Drugging Chemokine Receptors: Biased CXCR3 Agonists Differentially Regulate  
Chemotaxis  And Inflammation 
 
Jeffrey Smith, MD, PhD, Additional Authors:   Dylan Eiger, BS; Chia-Feng Tsai, PhD; Lowell Nicholson, MD; Ra-
chel Glenn, BS;  Priya Alagesan, BS; Amanda MacLeod, MD;  John Jacobs, PhD;  Tujin Shi, PhD;  
Sudarshan Rajagopal, MD,PhD 
 
Introduction: G protein-coupled receptors (GPCRs) are the largest class of transmembrane receptors and the 
target of ~30% of FDA approved drugs. It is now well established that GPCRs can signal through multiple trans-
ducers, including classical heterotrimeric G proteins but also GPCR kinases and β-arrestins (1). While these sig-
naling pathways can be activated or blocked by ‘balanced’ agonists or antagonists, they can also be selectively 
activated in ‘biased’ responses. This new GPCR signaling paradigm of ‘biased signaling’ heralds drugs with in-
creasing efficacy and fewer side effects (2). With over 50 ligands and 20 receptors, biased agonism is prominent 
within the chemokine system. Here, ligands and receptors bind one another with significant redundancy. For ex-
ample, the GPCR CXCR3 is expressed on activated T cells and has three established endogenous ligands: 
CXCL9, CXCL10, and CXCL11 (3,4). Despite its role in inflammation, infectious disease, and cancer (5), no ap-
proved drugs target CXCR3. The purpose of my research is to measure biased signaling at CXCR3 and assess 
the therapeutic potential of selectively targeting certain CXCR3 signaling pathways with biased agonists. 
Methods: Utilizing state-of-the-art transcriptomic and phosphoproteomic analyses (6), we show vast differences 
in CXCR3-regulated intracellular signaling. Responses were compared between vehicle, CXCL9, CXCL10, or 
CXCL11 treatment assessing >5,000 unique phosphopeptides and >13,000 genes. Biased responses were as-
sessed in both immortalized cell lines and primary human T cells. Utilizing various second messenger reporter 
systems and bioluminescence resonance energy transfer assays (2,3), we identify an important proximal GPCR 
signaling pathway, β-arrestin, and demonstrate that CXCL11 acts as a β-arrestin-biased agonist at CXCR3. Fur-
thermore, we screened small molecules to identify a G protein-biased and a β-arrestin-biased small molecule ago-
nist of CXCR3. We then utilized these small molecules to measure physiological readouts of inflammation and 
chemotaxis in both mice and patients. 
Results: Endogenous chemokines of CXCR3 activate divergent intracellular signaling pathways. Using both 
chemokines and small molecules, we show that β-arrestin pathway signaling through CXCR3 is necessary for full 
efficacy chemotaxis of activated T cells in both mice and patients (p<0.05). In addition, a β-arrestin-biased small 
molecule potentiated the cutaneous inflammatory responses in wild-type mice (p<0.05), but not in either β-arrestin 
KO (p=0.77) or CXCR3 KO (p=0.72) mice, indicating both CXCR3 and β-arrestin dependence in T cell mediated 
inflammatory responses. 
Conclusions: Here we show that CXCL9, CXCL10, and CXCL11 activate distinct CXCR3 intracellular signaling 
pathways with divergent physiological effects. We clearly demonstrate that the multiple CXCR3 chemokines, 
CXCL9, CXCL10, and CXCL11, are not redundant in their CXCR3 signaling properties. We show that non-
canonical β-arrestin signaling is necessary for certain CXCR3-regulated inflammatory responses and for chemo-
taxis in both mice and patients. These data strongly suggest that CXCR3 biased agonists have therapeutic prom-
ise to treat inflammatory conditions. 
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35.  Is Empiric Coverage With Vancomycin Necessary For Pneumonia? 
 
Hiromichi Park, DO, Shirin Ferdosian Najafabadi;  Lian Wang PhD;   
David Gilbert, MD, MACP 
 
Introduction: 
Currently Pneumonia accounts for 1.2 million hospitalizations every year with an estimated 63,000 
deaths. Empiric Vancomycin therapy is often employed as empiric therapy versus Methicillin-
resistant Staphylococcus aureus (MRSA). A nasal swab PCR is the current rapid screening test to 
detect MRSA.   The FDA recently approved a sputum FilmArray pneumonia PCR panel that can de-
tect MRSA, MSSA plus 17 other relevant bacteria, and 8 viral pathogens. The goal of this study was 
to compare MRSA detection by various methods.  
 
Methods: 
585 patients with Community Acquired Pneumonia (CAP) were enrolled to compare pathogen de-
tection with a “bundle” of tests versus the new 33 target FilmArray sputum pneumonia panel. Of the 
585 patients, 271 patients were evaluable for comparative detection of S. aureus via blood and spu-
tum culture, sputum pneumonia panel and nasal swab PCR. Other detected pathogens were report-
ed separately.  
 
Results:  
S. aureus was detected in 112 of 271 evaluable patients. The FilmArray pneumonia panel sampled 
from sputum detected 69 cases representing 62.2% of total evaluable cases. Nasal swab PCR de-
tected 92 cases representing 82% of evaluable cases. P value was 0.004 between tests. When the 
nasopharyngeal swab PCR test was considered as the gold standard for MRSA, Sputum PCR had 
a sensitivity rate of 63.9% with a negative predictive value of 94.7%.  
Species concordance (MSSA and MRSA) between S. aureus detected in nasal and sputum sam-
ples was 52/56 (92.3%) positive patients.  
 
Discussion:  
Nasal swab PCR testing had significantly higher sensitivity than sputum PCR in detection of S. au-
reus (both MSSA/MRSA).  Of clinical import, a negative nasal PCR for MRSA supports discontinua-
tion of empiric Vancomycin Therapy. Conversely, the lower frequency of MRSA detection with the 
sputum PCR creates uncertainty in decisions to discontinue Vancomycin therapy.  
 
Conclusion:  
Nasal PCR for S. aureus is more sensitive than sputum PCR for MSSA and MRSA. In a critically ill 
patient with influenza and elevated serum Procalcitonin level, it may be necessary to perform both a 
nasal S. aureus PCR (whether to discontinue empiric Vancomycin therapy) plus the sputum multi-
plex PCR for detection of other relevant bacterial pathogens. 
36.  Comparative Detection Of Airway MRSA In Patients  
With Community-Acquired Pneumonia (CAP) 
 
Hiromichi Park, DO, Shirin Ferdosian Najafabadi, Lian Wang, PhD, David Gilbert, MD, MACP 
 
Introduction: 
Vancomycin is often included in the empiric therapy of CAP to ensure activity against MRSA. The 
current gold standard for detection of MRSA in the airway is a nasal swab PCR. The FilmArray spu-
tum pneumonia panel includes PCR probes for MRSA. This study compares the detection perfor-
mance of the nasal swab versus the sputum PCR detection of MRSA. Clinically, the absence of air-
way-detectable MRSA allows cessation of empiric Vancomycin.  
 
Methods: 
585 patients with Community Acquired Pneumonia (CAP) were enrolled to compare pathogen de-
tection with a “bundle” of tests versus the new 33 target FilmArray sputum pneumonia panel. Of the 
585 patients, 112 patients were evaluable for comparative detection of S. aureus via blood and spu-
tum culture, sputum FilmArray pneumonia panel and nasal swab PCR.  
 
Results: 
The FilmArray pneumonia panel sampled from sputum detected 69 cases representing 62.2% of 
total evaluable cases. Nasal swab PCR detected 92 cases representing 82% of total cases. P value 
was 0.004 between tests. Sputum PCR had a sensitivity rate of 63.9% with a negative predictive 
value of 94.7% when nasal PCR was considered as the gold standard for MRSA detection. Con-
versely the nasal PCR had a sensitivity of 85.2% with negative predictive value of 98.3% when spu-
tum PCR is gold standard. Among cases that were simultaneously detected by nasal and sputum 
PCR, species (MSSA and MRSA) match rate was 52/56 (92.3%).  
 
Discussion: 
Nasal swab PCR testing had significantly higher sensitivity than sputum PCR in detection of S. au-
reus (both MSSA and MRSA). Of clinical import, a negative nasal PCR for MRSA supports discon-
tinuation of empiric Vancomycin Therapy. Conversely, the 20% lower frequency of MRSA detection 
with the sputum PCR creates uncertainty in decisions to discontinue Vancomycin therapy.  
 
Conclusions: 
Nasal PCR for S. aureus is more sensitive than sputum PCR for both MSSA and MRSA. In a criti-
cally ill patient with influenza and elevated serum Procalcitonin level, the most sensitive method to 
detect the presence of MRSA is a nasal swab PCR. 
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 37.  Diabetes Education with a Teaching Kitchen Intervention Can Improve Hemoglobin 
A1c for Type 2 Diabetics Compared to Traditional Diabetes Education 
  
Justin Ferley PGY2, Jill Christensen MD MPH, Heidi Davis MSW, Charlotte Navarre RN,  
Hsin-Fang Li PHD, Kathy Schwab MPH RDN, Richard O’Neil MBA  
 
Purpose  
The Providence Milwaukie Community Teaching Kitchen offers health-focused, budget friendly 
cooking classes for patients. In 2019, we piloted diabetes education classes with an added 
hands-on culinary session. This study compares the change in hemoglobin A1c for patients who 
participated in the pilot with those in the standard curriculum and those referred to diabetes edu-
cation but did not enroll.  
 
Methods  
This retrospective analysis compared change in hemoglobin A1c for all patients referred to dia-
betes education in the Providence Northern Oregon region in 2019. Patients referred to diabetes 
education but not enrolled were considered a control group. To balance patient characteristics 
(e.g. age, gender, and pre-A1c score), two-to-one propensity score matching method was used 
to identify two matched controls for each enrollee. Change in hemoglobin A1c from baseline to 3
-6 months were compared among matched comparison groups.  
 
Results  
13,582 patients were identified including 19 patients enrolled in diabetes education plus kitchen 
class, 640 patients in traditional diabetes education, and 12,923 patients referred but did not en-
roll. After matching, 1,318 matched patients were selected from the non-enrollees as the control 
group. The change in hemoglobin A1c was -0.49, -0.81, and -0.95 for the control group, diabetes 
education group, and diabetes education group with kitchen classes, respectively. Compared to 
the control group, both diabetes education groups had a greater reduction in hemoglobin A1c 
(difference of 0.32, 95% Confidence Interval [CI]=0.17, 0.48 for the diabetes education group; 
difference of 0.46, 95% CI=-0.28, 1.19) for the diabetes plus kitchen class group). Even though 
the diabetes education plus kitchen intervention had the largest reduction in hemoglobin A1c, 
the sample was small with large variation.  
 
Conclusions  
Integrating a teaching kitchen component into the traditional diabetes education curriculum is a 
promising approach that can further improve initial biometric outcomes. Future studies are war-
ranted to demonstrate clinical effectiveness of this enhanced intervention.  
 
Financial Support  
Health Share Oregon Coordinated Care Organization 
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38.  Development and implementation of take-home naloxone kit for patients admitted  
to the emergency department of a large tertiary care hospital  
  
Myung Seon (Amy) Song, PharmD; Pamela Levine, PharmD, BCPS; Katharine F. Marshall, MD; 
Chelsea Harmon, PharmD Candidate 2020 
Background/Purpose:    
In 2017, the United States Department of Health and Human Services (HHS) declared the 
opioid epidemic as a public health emergency as more than 70,000 people died from drug 
overdoses. Approximately 75% percent of unintentional opioid-overdose deaths occurred 
outside of a medical setting. In order to combat the opioid crisis, the US Surgeon General 
urged prescribers and pharmacists to increase access to naloxone for individuals who are at 
risk for opioid overdose. Community overdose education and naloxone distribution (OEND) 
programs have demonstrated that take-home naloxone kits are associated with reduced opi-
oid-overdose death rates and are cost-effective. From January 2016 – June 2019, about 
4,016 emergency department (ED) and urgent care visits in the Portland metropolitan area 
were identified to be due to opioid overdose. Recent data from the Centers for Disease Con-
trol and Prevention (CDC) indicates a continuing upward trend, making the ED a critical inter-
vention point for providers and pharmacists to engage patients with at-risk of opioid overdose 
and provide evidence-based interventions such as take-home naloxone kit. The primary ob-
jective of this study is to develop and implement a pharmacist driven take-home naloxone kit 
protocol. The secondary objective is to increase access to naloxone by prescribing and dis-
pensing kits to at-risk patients in the emergency department.   
 
Methods:  
A retrospective quasi-experimental, pre- and post-protocol analysis, will be used to compare the 
number of prescriptions written prior to implementation of protocol (April 1, 2017 to September 1, 
2019) to the number of take-home naloxone kit dispensed post implementation of the protocol. In-
clusion criteria include patients 18 years or older and admitted to ED for treatment of opioid over-
dose, or with risk factors of opioid overdose. The primary endpoint is number of naloxone prescrip-
tion written and take-home naloxone kits dispensed.  
 
Results:  
Key stakeholders were identified and engaged in developing the protocol. Operational and cost con-
sideration were reviewed. Various factors affected development and implementation of the study.  
 
Conclusions: Adaptation of parts of the study to take place in two large tertiary care hospitals.  
 
IRB status:  Pending 
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39.   Pharmacoeconomic impact of patient-centric oncology service model 
 
Kasey Rubin PharmD, ,Samuel Jacobson PharmD. BCOP, Shannon Buxell PharmD. 
  
Providence Health & Services recently embedded ambulatory oncology pharmacists into the ambu-
latory oncology clinic setting. The overall purpose of this retrospective study is to quantify the finan-
cial benefits of ambulatory oncology pharmacists as well as quantify patient-centric factors through 
utilization of an onsite specialty pharmacy. This study was submitted and approved by Institutional 
Review Board. Electronic health records of patients who visited the ambulatory oncology clinic will 
be retrospectively reviewed over two time periods: 12 months preceding integration of a pharmacist 
and 12 months post integration of a pharmacist on the ambulatory oncology team at Providence 
Portland Medical Center (PPMC). Each group will consist of 250 patients. The following patient data 
will be collected: Patient MRN, Patient visit encounter (if multiple visits), sex, ICD10 code for diag-
nosis, number of prescriptions/dispense report, cost of medication, financial revenue, nausea 
scores, pain scores, and number of Interventions completed by pharmacists. These endpoints will 
be assessed and an estimated dollar amount will be attached to each non-monetary service provid-
ed by pharmacists. Epic projects an equivalent dollar amount per each intervention completed by a 
pharmacists. This projected dollar amount will be utilized to quantify the benefits of a pharmacist 
and will be considered as cost-savings. Number of prescriptions/dispense report and cost data will 
be provided by Providence specialty pharmacy, Credena. Credena utilizes Epic and CPR+. The pri-
mary investigator will not access to CPR+ and will defer to secondary investigators to collect pre-
scription data.  
 
Preliminary pharmacoeconomic data will be presented. Clinical results from the addition of the phar-
macists show an initial review of the oral antineoplastic in 70% and 86% of patients in sites #1 and 
#2, respectively. Follow-up calls were made to 55% and 85% of patients in sites #1 and #2, respec-
tively. Patients getting their prescriptions through Credena are continually counseled by Credena 
specialty pharmacists. Pharmacists reviewing medications reviewed drug-drug interactions, with the 
true number of interventions not able to be calculated. In conclusion, pharmacists have added both 
financial and patient centered benefits after integration with the care team.  
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40.  Empowering caregivers to recognize, support, and treat opioid use disorder:  
an interdisciplinary assessment of knowledge, attitudes, and comfort level  
pre and post-education 
 
Annette Sprankle, PGY1 Pharmacy Resident, PMMC 
 
Background: Substance use disorder affects approximately one in every four hospitalized patients. 
These patients are often treated for the admitting medical issue without addressing their substance 
use disorder. A hospital admission provides an opportunity to connect patients to the medical sys-
tem. Evidence demonstrates that starting medication-assisted treatment in the hospital reduces the 
risk of overdose upon discharge, rate of hospital readmission, length of stay, and hospital expendi-
tures.  
Purpose: The purpose of this study is to assess how providing education to the interdisciplinary 
team affects their knowledge, attitudes, and comfort level of treating patients with opioid use disor-
der in the hospital.  
Methods: This study has been approved by the Institutional Review Board. A formalized pre-
education survey was developed and administered to members of an interdisciplinary team on a 
voluntary basis. Members include pharmacists, hospitalists, nurses, social workers, and case man-
agers. Attitudes regarding medication-assisted treatment, baseline knowledge, and comfort level of 
treating patients with opioid use disorder were assessed. Interdisciplinary education modules were 
developed and presented to the team by the resident including the identification, treatment, monitor-
ing, follow up, and education of patients with opioid use disorder. A post-education survey was ad-
ministered to reassess the same parameters as the pre-education assessment. Prescribing data for 
initiation of buprenorphine and methadone was analyzed comparing data for a 3-month time frame 
before education and a 3-month time frame after education was provided. Pregnant patients or pa-
tients under 18 years of age were excluded from this analysis. A Mann-Whitney test was used to 
analyze each question rated on a Likert scale. A one-tailed test was utilized with a p-value of <0.05 
set as the threshold representing statistical significance.  
Results: Fifty-nine caregivers answered a pre-education survey and nineteen caregivers participat-
ed in the post-education survey. All disciplines reported an increase in knowledge base after receiv-
ing education. This was determined by question one (p=0.0222), two (p=0.00049), four 
(p=0.00075), and five (p=0.00706) of the survey. Comfort level measured by question six of the sur-
vey was not unanimous for increased comfort (p=0.299). Nurses reported increased confidence in 
recognizing the symptoms of withdrawal (p=0.0178), comfort asking patients about their withdrawal 
(p=0.0392) and comfort in administering the clinical opiate withdrawal assessment (p=0.0108) after 
education. Pharmacists reported increased confidence in speaking to the advantages and disad-
vantages of buprenorphine versus methadone (p=0.0129) and comfort in providing dosing recom-
mendations (p=0.0402). Case managers and social workers had no change in feelings that there is 
an adequate outpatient pathway to connect these patients to care upon discharge. No hospitalists 
participated in the post-education survey. Two patients in three months were initiated on medication
-assisted treatment before education. Four patients were initiated in the three months after educa-
tion was provided 
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41.  Clinical Pharmacist-Led Intervention to Improve Statin Metric for Secondary Prevention 
at  Providence Medical Group – Southern Oregon Region 
 
Chloe Nguyen, PharmD, Judy Wong, PharmD, BCACP, and Karen White, PharmD, BCACP 
 
Background: Currently, there is a gap in meeting the statin metric at Providence Medical Group in 
Southern Oregon Region. The purpose of this project is to identify intervention strategies to improve 
statin metric for secondary prevention among patients with clinical atherosclerotic cardiovascular 
disease (ASCVD). 
 
Methods: This quality improvement project was approved by the system’s Institutional Review 
Board. Patients at least 18 years of age with diagnosis of clinical ASCVD not prescribed statin ther-
apy or prescribed sub-optimal statin therapy were included. Different strategies were implemented 
at Central Point Family Medicine Clinic. A presentation was delivered to the providers in late De-
cember to address barriers with statin prescribing. Pre- and post-surveys were collected to assess 
the effectiveness of the presentation and knowledge of providers regarding statin prescribing in pa-
tients with clinical ASCVD. Chart reviews were performed in January on identified patients to pro-
vide recommendation to providers. The primary outcomes were to assess impact of academic de-
tailing intervention on perceived barriers on statin initiation or optimization via pre- and post-surveys 
and to calculate the percentage of approved recommendation from providers. The secondary out-
come was the percentage of statins prescribed per each intervention strategy: refer to clinical phar-
macist for management, discuss statin therapy during the next appointment with provider, or update 
problem list and medication list.  
 
Results:  Prior to the intervention, a majority of providers believed that statins caused myopathy, 
liver injury, and rhabdomyolysis which can influence their decision when prescribing statin therapies 
and discussing statin treatment with patients.  Post-survey results showed a slight decrease in be-
lief that statins cause myopathy, liver injury, incidental diabetes, cognitive impairment and rhabdo-
myolysis. In addition, providers were more likely to retry a different statin or at a lower dose if pa-
tient had a documented intolerance to previous statin therapy following education.  
 
In a sample of 35 chart reviews, 5 patients were receiving sub-optimal statin therapies, 7 had docu-
mented reason for statin intolerance, and 3 were not candidates to receive high intensity statin. A 
majority of recommendations were approved by providers. The most common intervention chosen 
by providers (51.4%) was to discuss statin options with patient in next office visit. However, no 
changes were observed from this intervention. Out of the 10 patients who were referred to clinical 
pharmacy services for management, 5 declined statin and 4 were unable to reach. Only one patient 
was successfully started on high intensity statin.  
 
Conclusions:  Beliefs and approaches to statin discussions are varied among PCPs and can be 
contributing factors for statin initiation or optimization. These results highlight the complexity of find-
ing interventions that would be most successful for improving statin metric for secondary prevention 
among patients with clinical ASCVD. Nonetheless, we can be vigilant about working with providers 
to provide recommendations for the remaining patients with clinical ASCVD and create appropriate 
follow-up plans for those who were unable to be reached and those who do not have upcoming ap-
pointment with providers.   
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42.   Education of heparin per pharmacy guidelines to increase compliance, safety, and phar-
macists’ management of heparin infusions 
  
Christopher Truong, PharmD and Braxton Mehl, PharmD, BCCCP 
  
Background: 
Element of Performance 4 of The Joint Commission’s National Patient Safety Goal 03.05.01 re-
quires that hospitals have a written policy that addresses the need for baseline and ongoing labora-
tory tests to monitor and adjust anticoagulant therapy. Our hospital has a written Anticoagulation 
Management General Operating Policy for heparin orders managed through nursing or pharmacy. 
Currently, most heparin orders are nurse-managed and have resulted in lab and dosing errors.  
 
Purpose: 
The purpose of this project is to educate pharmacists on the Providence Oregon Region Heparin 
Guidelines as our hospital moves towards increasing pharmacists’ management of heparin infu-
sions. 
 
Methods: 
Pharmacists were trained in the Providence Oregon Region Heparin Guidelines through an educa-
tion session and quiz that required application of the heparin guidelines. A post-education survey 
was administered to each pharmacist that received training. Scores from the survey were tallied to 
assess the effectiveness of the training. After the session, the heparin-per-pharmacy order was 
made available at our facility and pharmacists’ adherence to the guidelines were evaluated.  
The primary outcome was the results from the post-education survey. Secondary outcomes include 
the number of heparin per pharmacy orders and adherence to the heparin guidelines by assessing 
the required baseline and follow-up labs and the appropriate loading, initial, and adjustment doses. 
Other secondary outcomes include time to therapeutic aPTT, signs or symptoms of bleeding or 
bruising, and the number of progress notes completed by pharmacists.  Primary and secondary out-
comes were analyzed with descriptive statistics. This project is IRB approved.  
 
Results: 
Eight pharmacists completed post-education surveys. The average pre-education survey score was 
2.9 out of 5 and the average post-education survey score was 4.4 out of 5, resulting in an average 
1.5 score improvement after attending the education session. Pharmacists scored the practice quiz 
and education session’s helpfulness as 4.4 out of 5 and 4.8 out of 5 respectively.  
Between February 20, 2020 and April 9, 2020, there were 11 heparin per pharmacy orders. Phar-
macists managed 9 orders and 2 orders were not verified by pharmacy. Required baseline and fol-
low-up labs were ordered in 100% of orders. Appropriate initial bolus and infusion doses were or-
dered in 100% of orders. Appropriate adjustment doses were ordered in 88.9% of orders. The aver-
age time to therapeutic aPTT was 12.68 hours. No signs or symptoms of bleeding were noted. A 
total of 68 heparin progress notes were completed by pharmacists.  
An education session and quiz were effective methods in training pharmacists to a heparin per 
pharmacy system guideline.  
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43.   Incorporating a clinical pharmacist in an outpatient palliative care team 
 
Crystal Rim, PharmD; Sharon Leigh, PharmD, BCPS; Linda De Sitter MD, MPH; Mary Grant, ANP; 
Dana Nguyen, PharmD 
 
Palliative care is a growing field in medicine that focuses on delivering care that improves quality of 
life for patients with serious illnesses. Often, the goals of palliative care differ from traditional goals 
of medicine. Currently, there is limited data demonstrating the integration of pharmacists in the palli-
ative care setting.  The purpose of this quality improvement is to evaluate the clinical pharmacist ’s 
role within an outpatient palliative care team when performing medication reconciliation and review. 
Medication review includes de-prescribing high-risk medications and optimizing medications in 
symptom management. Between January and February 2020, the clinical pharmacist interviewed 
patients referred to the outpatient palliative care service through three different methods: telehealth, 
pharmacy consult and telephone. The clinical pharmacist provided recommendations to the outpa-
tient palliative care nurse practitioner and primary care provider for medication optimization, symp-
tom management and de-prescribing based on STOPPFrail and Beers Criteria. Data from 19 pa-
tients were analyzed. One patient was excluded from analysis due to death. Five patients were in-
terviewed through telehealth. Two patients were directly consulted for pharmacist review by the out-
patient palliative care nurse practitioner. Seven patients were interviewed through telephone, of 
which 4 patients were referred to hospice following palliative care consult.  Of 19 patients, 64 total 
recommendations (29 medication discontinuation, 30 medication optimization, 5 symptom manage-
ment) were made. Six recommendations were accepted by the provider (3 medication discontinua-
tion, 3 medication optimization). The average time spent on chart review for each patient was 1.5 
hours. Pharmacist involvement in outpatient palliative care may be valuable. However, many barri-
ers to providing meaningful interventions were identified in this study. While telehealth provided the 
convenience to the patient and caregivers, utilization was limited due to lack of standardization of 
technology. Telephone interviews allowed proper medication reconciliation prior to the palliative 
care visit, but non-medication related issues may be prioritized after the visit. Finally, pharmacy con-
sult from palliative care nurse practitioners allowed more efficiency, but it did not allow formal phar-
macist integration in the outpatient palliative care team. Further studies quantifying the pharmacist 
role in outpatient palliative care are warranted.  
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44.    Evaluation of a two-way, HIPAA-compliant text-messaging platform in a  
health system specialty pharmacy 
 
DJ Clark, PharmD, PGY1, Adam Saulles, PharmD, CSP, BCACP;  
Tara Berkson, PharmD, BCACP 
  
Evaluation of a two-way, HIPAA-compliant text-messaging platform in a health system specialty 
pharmacy 
Specialty medications, including those used to treat Multiple Sclerosis (MS), represent a growing 
proportion of prescription drug expenditures in the United States. MS is a chronic, progressive con-
dition that requires maintenance therapy with disease-modifying medications. Many patients with 
MS rely on specialty pharmacies to obtain, dispense, and perform the necessary monitoring for 
these complex medication regimens. A study performed in 2017 by Munsell et al, demonstrated that 
only ~50% of patients with MS are adherent to prescribed regimens when initiating disease-
modifying therapy. Routine pharmacy outreach could potentially help improve medication adher-
ence in a population at high risk of disease progression secondary to non-adherence. Prior to July 
2019, this health system specialty pharmacy only contacted MS patients via phone call to perform 
refill coordination and pharmacist follow-up. This strategy has been effective, but is not without 
flaws. Oftentimes, patients prefer not to receive phone calls or are unavailable during pharmacy 
business hours. This can lead to repeat outreach phone calls from caregivers and gaps in therapy. 
In July 2019, a HIPAA-compliant messaging platform was implemented. With this program, patients 
can respond to refill inquiries at their convenience and provide typed responses to medication-
related safety, adherence, and efficacy follow-up questions sent by specialty pharmacists. This pro-
ject seeks to identify whether implementation of the aforementioned messaging platform has had a 
quantifiable benefit on patient outreach and workflow outcomes within a health system specialty 
pharmacy setting. This single center, retrospective cohort analysis evaluated adult patients with a 
diagnosis of MS and at least 2 dispenses of disease-modifying medications. Data was collected via 
the electronic health record and the implemented text messaging application. The primary outcome 
is time between pharmacy technician outreach and medication refill. Secondary outcomes include 
medication adherence reported as medication possession ratio (MPR), the proportion of patients 
enrolled in the specialty pharmacy’s patient management program, patient satisfaction, and phar-
macy phone call volume. Between group differences were described using simple descriptive statis-
tics and T-tests, where applicable. A total of 335 patient had fills prior to and post-implementation of 
the text messaging platform, and 313 had multiple fills in each category, allowing for calculation of 
MPR. Response time (HH:MM ± 95% Confidence interval) was significantly decreased with utiliza-
tion of text-message refill reminders (32:03 ± 7:09 vs 68:34 ± 11:37; p<0.001). Patients also had a 
higher MPR when utilizing the text-messaging platform (0.94 ± 0.01 vs 0.90 ± 0.02; p<0.001). A 
higher proportion of patients were enrolled in the pharmacy’s clinical management program after 
implementation of the text-messaging platform (82% vs 61%). A positive impact on patient satisfac-
tion was realized via surveys, while call volume was not reduced overall. This HIPAA-compliant text
-messaging platform is being utilized to successfully improve patient response time for refills, treat-
ment adherence, and overall engagement with clinical pharmacy services, while delivering a posi-
tive patient experience. These results will be pivotal in expanding use of a text-messaging platform 
to patients filling specialty medications for other conditions. (IRB Approved) 
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45.   Evaluation of surgical antibiotic prophylaxis at a large, tertiary medical center 
      
 Emily Fox, PharmD, PGY-1, Brent Footer, PharmD, BCPS; Angel Mendez, Pharmacy Student  
 
Surgical site infections (SSI) are a significant cause of morbidity, prolonged hospitalization, and 
mortality. The cost of a single SSI is estimated to be upward of $25,000 and increases a patient ’s 
length of hospital stay by ~10 days. Our institution has identified inappropriate or less than optimal 
antimicrobial prophylaxis as a potential contributor in several recent SSI cases. Current literature on 
this topic has found that there may be a role for clinical pharmacists in cyclic auditing to improve 
surgical antibiotic prophylaxis guideline adherence. This retrospective analysis of hysterectomy, col-
orectal, and spinal surgeries aims to review surgical antimicrobial prophylaxis for appropriateness 
based on patient-specific factors and published system and national guidelines.  
This is an IRB-approved, single institution retrospective chart review of surgical antibiotic prophylax-
is regimens for adult patients that underwent hysterectomy, colorectal, or spinal surgery between 
the months of June and August 2019. Specific surgery types were chosen based on requests by 
surgery leadership and highest potential for quality improvement. Patients were identified by sur-
gery classification via the electronic medical record (EMR). Other relevant data was obtained via the 
EMR including: surgeon, anesthesiologist, antibiotic regimen, dose, administration time, ordering 
method, and patient weight. Additional chart review was required for other relevant factors including 
history of multi-drug resistant organisms and allergy history/severity. The primary outcome meas-
ured was compliance to hospital system guidelines, accounting for antibiotic selection, administra-
tion timing, and dosing.  
Primary outcome adherence rates varied greatly depending on the type of surgery. For hysterecto-
my, 62 of 141 surgeries (44%) achieved the primary outcome, with the primary contributor of non-
compliance being selection of an antibiotic regimen inconsistent with system-wide guidelines. For 
colorectal surgeries, 21 of 35 (60%) achieved the primary outcome, with the primary reason for non-
compliance being inappropriate antibiotic administration timing. Additionally, it was identified that 
history of resistant infections was not properly accounted for when making antibiotic prophylaxis 
choices, with 3 SSIs resulting from multi-drug resistant organisms in patients with MDRO history. 
Spinal surgery compliance to the primary outcome was less-clear, as guidelines are not as well-
defined. However, MRSA colonization status was not determined via PCR when appropriate for 31 
of 148 (21%) of surgeries.  
Opportunities for pharmacist intervention and education were identified for implementation after 
chart review of each surgery. Each surgery requires a unique intervention. Primary outcome data 
and proposed interventions for each surgery was presented to the institutional surgical site infection 
committee, which met quarterly. Pharmacist cyclic auditing of antibiotic prophylaxis choices resulted 
in increased discussion and education. Proposed changes are still being considered by surgery de-
partment leadership, including a change in antibiotic choice for colorectal surgeries. Future data col-
lection will be performed after changes are implemented to determine improved guideline adher-
ence.   
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46.  Safe Opioid Prescribing at Discharge 
 
Taylor Goodman, PharmD, Elva Van Devender, PharmD; Luetta Jones, PharmD; Courtney Barber 
 
Background/Purpose: The opioid epidemic has led to devastating consequences, especially in Or-
egon, with an average of five Oregonians dying each week from opioid overdose. Opioid prescrip-
tions at discharge are correlated with future continued opioid use. United States providers prescribe 
more opioids both inpatient and at discharge than other countries, and Oregon providers wrote 
more opioid prescriptions per person than the national average. Oversupplying prescription opioids 
can lead to reservoirs of unused medication, creating opportunities for non-medical use and over-
dose. Pharmacy interventions have shown significant improvement in safe opioid prescribing prac-
tices at hospital discharge. However, inpatient discharges still represent a major source of high-
volume opioid prescriptions. The purpose of this study is to evaluate hospital discharge opioid pre-
scriptions and to assess the impact of data sharing and education on subsequent discharge pre-
scribing practices. 
 
Methods: This was a retrospective review of discharge opioid prescriptions for adult hospitalist pa-
tients discharged from two, large, tertiary hospitals during July 2018, September 2019, and either 
February 2020 or February 18th thru March 18th, 2020 depending on the location. Eligible patients’ 
data elements including discharge opioid, quantity of opioid tablets (QTY), morphine milligram 
equivalence (MME), concomitant benzodiazepine prescription, ordering provider, and ordering de-
partment were evaluated for pre and post intervention implementation analysis. Data was collected 
through a review of orders in the electronic health record (EHR). Further investigation into charts 
was completed for necessary additional information if needed. The primary outcome is hospitalist 
group opioid discharge prescribing practices pre and post multiple interventions (EHR changes to 
default quantity on new orders, addition of MME daily calculation and provider education) and pro-
vider education alone presented on either January 21st or February 11th, 2020. Secondary out-
comes include department and individual provider prescribing practices. This study has been ap-
proved by the institutional review board. 
 
Results: At Hospital A, both the average quantity of tablets and MME per discharge decreased post 
EHR and education interventions, then increased (25.8 to 23 to 25 and 198.3 to 177.5 to 195.6 re-
spectively) post education only intervention. At Hospital B, a similar trend in both the average quan-
tity of tablets and MME per discharge post interventions (34.9 to 23.3 to 25.8 and 303.5 to 191 to 
212 respectively) was seen. The percentage of <30 tablet discharge prescriptions also overall de-
creased (62% to 62.7% to 67.5% at Hospital A and 50.6% to 70.2% to 66.5% at Hospital B). 
 
Conclusion: Results comparison prior to intervention (2018) to post intervention (2019 and 2020) 
indicate that it was effective in promoting safer prescribing practices however education/data shar-
ing only intervention may be more effective when combined with more system orientated interven-
tions. While longer term monitoring and individual provider follow up is needed to elicit the true im-
pact of provider education and data sharing intervention, future efforts should combine multiple in-
terventions. These should target the individual via continued education/data sharing and system 
processes via workflow adjustments such as encouraging utilizing new opioid orders upon dis-
charge. Targeting specific service lines could help identify more opportunities to promote safer pre-
scribing practices going forward. 
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47.  Evaluation of Guideline-Directed Medication Therapy for Heart Failure with Reduced 
Ejection Fraction Patients at Discharge on 30-Day Readmission Rates at Two Tertiary 
Healthcare Centers 
Jacqueline Hesse, Pharm.D., Yan Xu, Pharm.D., BCPS, BCCP; Meri Slavica, Ph.D., BCPS,  
James Watkins, 2020 Pharm.D. Candidate, Alan Rankin, MD; Joshua Remick, MD 
 
Background:  Heart failure with reduced ejection fraction (HFrEF) is a chronic, progressive disease leading 
to symptoms such as dyspnea, cough, edema, fatigue, and exercise intolerance. The use of anangiotensin 
converting enzyme inhibitor (ACEi), angiotensin II receptor blocker (ARB), or angiotensin receptor-neprilysin 
inhibitor (ARNI) in combination with an evidence-based beta blocker (BB) is guideline-supported Class I rec-
ommended therapy for HFrEF with an LVEF <40%. Multiple studies with the combination of these medication 
classes have shown improvement in HFrEF patient morbidity and mortality, as well as decrease in hospital 
readmission rates. In 2019, the readmission rate for any heart failure diagnosis within 30 days is 13.6%-
15.07% at these tertiary medical centers. Approximately 50% of these total HF admissions are estimated to 
be due to HFrEF. Prior scientific literature supports the clinical benefits appropriate, safe, and guideline-
directed medication therapy (GDMT) with an ACEi, ARB, or ARNI with or without a BB, particularly as it per-
tains to HFrEF-related readmissions and mortality, but has not yet been studied at our two tertiary medical 
centers. 
 
Methods: A retrospective chart review was completed using the Epic Electronic Medical Record of all pa-
tients admitted to one of our tertiary medical centers between January 1, 2018 and December 31, 2019 with 
a primary diagnosis of HFrEF. Patients were included if they were at least 18 years of age and had an LVEF 
of <40%. Patients were excluded if they had a history of angioedema as a result of ACEi, ARB, or ARNI use, 
or any hypersensitivity or unacceptable side effect to an ACEi, ARB, ANRI, or BB. Readmission to one of our 
tertiary medical centers within 30 days of discharge within this time frame, as well as the guideline-directed 
medication therapy a patient was discharged on was recorded. Secondary endpoints of highest serum creati-
nine (SCr), highest potassium (K), and lowest systolic blood pressure (SBP) were also collected if a patient 
was readmitted within 30 days of discharge, and cause of HFrEF and incidence of angioedema were collect-
ed for all patients meeting inclusion criteria. 
 
Results:  A total of 1,999 patient admissions underwent chart review with 752 admissions not meeting inclu-
sion criteria and 1,247 admissions being included in the final analysis. Of those included, 202 patients (16%) 
were readmitted within 30 days. Patients discharged with any GDMT had less readmissions within 30 days 
than those without any GDMT (OR 0.6, 95% CI 0.4-1.0, p = 0.0369). However, patients discharged on an 
ACEi or ARB had more readmissions within 30 days than patients discharged on no GDMT (OR 1.4, 95% CI 
1.0-1.9, p = 0.0283). 49% of patients (N = 609) had an idiopathic cause of heart failure followed by 32% of 
patients with non-ischemic cardiomyopathy (N = 394) and 20% of patients with ischemic cardiomyopathy (N 
= 244). No significant differences were found between the 30-day readmission rate and cause of heart fail-
ure. For highest K value on readmission, no significant differences were found between groups. For highest 
SCr on readmission, discharging on an ACEi or ARB or discharging on an ACEi or ARB in combination with 
a BB yielded a significantly lower SCr on readmission compared to no GDMT (1.6 vs. 2.6, p = <0.0001 and 
1.7 vs. 2.4, p = 0.0002, respectively). The combination of ARNI and BB compared to no GDMT was also sta-
tistically significant for lower SCr (1.7 vs. 2.2, p = 0.0443). For lowest SBP on readmission, discharging on a 
BB or discharging on any GDMT yielded a significantly higher SBP on readmission compared to no GDMT 
(89.6 vs. 82.1, p = 0.0135 and 89.1 vs. 78.1, p = 0.0081, respectively). Lastly, no significant differences were 
found between groups in the incidence of angioedema. 
 
Conclusion:  In conclusion, patients admitted with a primary diagnosis of HFrEF that are discharged on any 
GDMT were found to have less readmissions for any reason within 30 days than those without any GDMT. 
However, subgroup analysis for individual GDMT may not have a lower rate of readmissions. Further re-
search with prospective randomized controlled trials is needed to determine statistical significance of sub-
groups of GDMT on the rate of readmission within 30 days.   
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48.  Effect of a pharmacist-led antimicrobial stewardship (AMS) program on outpatient  
fluoroquinolone prescribing in the elderly 
 
LaRue, Katie PharmD; Mannebach, Chelsea PharmD, BCPS, BCACP;  
Jiron, Bonnie, PharmD, BCACP  
 
Introduction: The Center for Disease Control and Prevention, the Society of Infectious Diseases 
Pharmacists, and American Pharmacists Association recognize the need for outpatient AMS pro-
grams and the important role pharmacists play in appropriate prescribing. Fluoroquinolones (FQ) 
pose many risks, highlighted by U.S Food and Drug Administration safety warnings, including aortic 
dissection, hypoglycemia, mental health side effects, and tendonitis, along with the risk of Clostridi-
um difficile infections, particularly in the elderly. 
 
Outcomes: The primary outcome is to determine the change in the number of FQ prescriptions 
written for patients ≥65 years of age in the primary care setting between March 2018 and 2019, and 
March 2019 and 2020. Secondary objectives include determining the appropriateness of fluoroquin-
olone prescriptions before and after education intervention, and provider attitudes towards outpa-
tient AMS. 
 
Methods: Education on fluoroquinolone antibiotic risks, safety warnings, and guideline-directed us-
es was provided to prescribers in February 2020. During education, prescribers were given a report 
of the number of fluoroquinolones prescribed to patients ≥65 years of age during March 2018 and 
March 2019 with comparison to other prescribers.  Data was collected for March 2020 and a similar 
report was given to prescribers. Approximately 15% of fluoroquinolone prescriptions were reviewed 
for secondary outcomes. Changes in fluoroquinolone prescriptions will be analyzed by Bayesian in-
ference and secondary outcomes will be reported with descriptive statistics.  
 
Results:  There was a decrease in the total number of fluoroquinolone prescriptions in March 2020 
(n=134) compared to March 2019 (n=200) and March 2018 (n=272). After secondary review of 15% 
of these prescriptions, there was an increase in appropriately prescribed fluoroquinolones from 
2.4% in March 2018 (n=41) to 27.8% in March 2020 (n=18).  Of 118 providers surveyed before and 
after the educational presentation, 6.8% correctly identified all risks associated with fluoroquinolone 
therapy prior to the education and 84.1% correctly identified all risks associated with fluoroquino-
lone therapy after receiving education.  After the education, an increase in providers reported being 
very comfortable discussing the risks and benefits of FQ therapy with their patients, from 23% prior 
to the education to 65% after the education. 
 
Conclusions: Provider education on risks associated with fluoroquinolone use in the elderly and 
individualized provider reports was associated with a decrease in total fluoroquinolones prescribed 
to patients ≥65 years of age in the included primary care clinics. Additionally, a higher percentage of 
fluoroquinolones were prescribed appropriately based on evidence-based guidelines. Ongoing AMS 
efforts are needed to continually improve patient safety and reduce unnecessary antimicrobial expo-
sure. 
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49. Evaluating outcomes of medication-related interventions from the “Seniors At risk for 
Falls after Emergency Room visit” (SAFER) pilot project  
 
Ling J. Zhan, PharmD, Sharon Leigh, PharmD BCPS, Mary Beth Kuebrich, MS, AGPCNP-BC, 
Clara Mikhaeil, PharmD, BCPS, Colleen M. Casey, PhD, ANP-BC 
  
 Purpose: Falls are the leading cause of injury in older adults, resulting in decreased mobility, loss 
of independence, and increased health care costs. Even a single fall puts an older adult at higher 
risk for future falls. Despite numerous studies showing evidence that multifactorial fall risk interven-
tions are effective in decreasing fall risk, even older adults who have an injurious fall often do not 
receive meaningful interventions to mitigate their fall risk. This study evaluated the impact of medi-
cation-related interventions for older adults who had a fall-related ED visit, as part of a larger study 
of multifactorial fall-risk interventions in the primary care setting. 
 
Methods: This study was approved by the Providence-Oregon Institutional Review Board. This ret-
rospective chart review studied a subset of patients enrolled in the SAFER pilot project who pre-
sented to an ED following a fall. Included patients were 75 years or older and taking at least one 
high-risk medication (HRM) that is associated with increased risk for falls. Patients were enrolled in 
the SAFER pilot from December 2018 to June 2019. Eligible patients received a comprehensive 
medication review by a clinical pharmacist; some also received a Geriatric consult that included 
medication recommendations. Medication recommendations were then forwarded to the clinic’s Pri-
mary Care Provider (PCP) and Registered Nurse for follow up. The parent study used a matched 
control design to compare SAFER interventions with usual care; this study did not include a com-
parison to the control group. Study outcomes included: overall burden of high-risk medications, 
number of high-risk medications discontinued or tapered, initiation of osteoporosis treatment or pre-
vention measures, changes in blood pressure (BP) or hemoglobin A1c goals, and overall reduction 
in polypharmacy. The study also evaluated to what degree medication-related recommendations 
were adopted by the PCP over a minimum follow-up period of 7 months.  
 
Results: Overall, 50 patients underwent chart review with 4 patients not meeting inclusion criteria; 
46 patients were on HRM (average 4.3 HRM/person) and included in the final analysis.  
Of those patients, 25 (54%) received a PharmD consult. For these 25 patients, 117 medication-
related recommendations were made by the Geriatric and Clinical Pharmacy teams. Of those, a to-
tal of 52 (44%) changes were implemented by the PCP: 17 HRMs were discontinued, 9 taper/cross-
tapered, and 17 osteoporosis-related initiated. BP and A1c goals on patient’s problem list were not 
clearly defined for 69% and 50% of patients, respectively.  
 
Conclusion: Medication optimization and reduction of HRM was effective in patients receiving a 
PharmD consult. The most accepted recommendations included ordering DEXA, orthostatic BP 
testing, adding Vitamin D, and discontinuing opioids. Not every patient who qualified received a 
PharmD consult, suggesting that more medication changes could have been implemented had 
PharmDs been involved. The process of referring to a PharmD for a consult will need to be re-
viewed. Given that these patients are at high risk to fall, BP and A1c goals should be clarified and 
perhaps more lenient goals may be indicated. In addition, these results should be compared with 
the matched-control group of the parent study to determine the value of reducing HRM use in older 
patients at high risk of falls. 
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50.   Evaluation of late-onset sepsis antibiotic utilization and revision of empiric late-onset 
sepsis antibiotic prescribing guidelines 
Alex Creevan, PharmD, Michael Garcia, PharmD, Angela Roberti, PharmD, Sara Clark, PharmD, 
Anavice Jimenez, PharmD Candidate 
  
Neonatal late-onset sepsis (LOS) is commonly defined as an infection occurring after the first 72 
hours of life. Late onset sepsis is a common complication of prolonged admission to the neonatal 
intensive care unit (NICU) and is a major cause of morbidity and mortality. Due to risks associated 
with LOS, empiric antibiotics can be inappropriately prescribed, which may lead to multi-drug re-
sistant bacteria, increased healthcare costs, alterations in microbiome, increased risk of necrotizing 
enterocolitis (NEC) and mortality. Current Providence Oregon regional guidelines for suspected 
LOS in the NICU do not provide clear prescribing or antibiotic dosing recommendations, have not 
been updated since 2011, and are underutilized by providers.  All of which can lead to inappropriate 
antibiotic prescribing. Providers at two tertiary medical centers agreed upon using American Acade-
my of Pediatrics (AAP) Red Book for antibiotic dosing in October 2019. A retrospective chart review 
was conducted to evaluate the appropriateness of antibiotic utilization in the NICU at two tertiary 
medical centers, and to promote standardization of antibiotic prescribing for LOS through revision of 
the 2011 regional empiric antibiotic guidelines for suspected LOS in the NICU. This study was ap-
proved by the institutional review board. Patients admitted to the NICU between September 1, 2016 
through August 31, 2019 with confirmed or suspected LOS who received at least one dose of em-
piric antibiotics starting after 72 hours of life were included in the study. The primary outcome is to 
measure the appropriateness of antibiotic utilization compared to the 2011 Providence Oregon Re-
gional guidelines and recommendations from the neonatal antibiotic dosing references AAP Red 
Book, Lexicomp, Neofax, or “other” if dosing did not match one of the specified reference. The sec-
ondary outcome measure of revision and implementation of new late-onset sepsis guidelines is still 
in progress. Exploratory outcomes include antibiotic selection, indication, and duration of therapy. 
Patient data such as risk factors for LOS, diagnosis, gestational age, postnatal age and postmen-
strual age at time of antibiotic initiation, birth weight, blood culture and susceptibilities, and out-
comes such as mortality, transfer to a higher level of care, discharge home, and further courses of 
antibiotics were also included as exploratory outcomes. Thirty-five patients were identified as having 
at least one instance of LOS, and there were 45 instances of LOS total, as some patients had more 
than one occurrence. After excluding antibiotics dosed by pharmacy (vancomycin and gentamicin), 
55 antibiotics were evaluated based on neonatal antibiotic dosing reference. For the primary out-
come, 47% (21) empiric antibiotic regimens did not correspond with the 2011 guideline. Fifty-three 
percent (29) of antibiotic dosing matched AAP Red Book recommendations, 29% (16) matched 
Neofax, 5% (3) matched Lexicomp, and 13% (7) other. Nearly half of the empiric antibiotic regimes 
were not consistent with 2011 Regional guidelines. These inconsistencies are likely attributable to 
the vagueness of the guideline. In addition, while the majority of dosing matched AAP Red Book, 
antibiotic dosing reference utilization was highly variable.  Prescribers would likely benefit from a 
standardized guideline for prescribing empiric antibiotics based on AAP Red Book dosing recom-
mendations.  
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51. Clinical Impact of an HIV Specialist Pharmacist Collaborative Practice Agreement: a 1-
year Retrospective Review of Interventions 
 
Rebekah Batholomew, PharmD, GeofFrey L’Heureux, PharmD, AAHIVP,  
        Brent Footer, PharmD, BCPS 
 
 
Purpose/Background: 
HIV continues to be one of the most complex disease states for patients and providers to manage. 
With new medications and guidelines being routinely updated, ensuring that patients are on optimal 
anti-retroviral therapy (ART) throughout their lives can be difficult. Previous studies on pharmacist-
led HIV services have shown that utilizing a pharmacist to manage ART is beneficial. The purpose 
of this study is to add to that body of evidence by analyzing the clinical impact of a nascent collabo-
rative practice agreement for an HIV specialist pharmacist to manage patients seeking care related 
to HIV.  
 
Methods: 
This study was granted exempt status by the Providence Institutional Review Board. An electronic 
health record was utilized to identify patients whom were seen at an HIV clinic under the manage-
ment of a pharmacist. Chart reviews were conducted to collect and analyze pharmacist interven-
tions. Data collected included the following: number of ART changes (and rationale for each change 
to be categorized as for efficacy, safety, or simplification reasons), number of patients seen for HIV/
AIDS, PrEP, and PEP, number of patients enrolled in medication assistance programs (MAPs), HIV 
viral loads (VLs) and CD4+ cell counts over 1 year (each patients’ level of control to be classified as 
improved, worsened, or no change), number of co-morbid disease state medication modifications, 
and number of coordination of care interventions. The data was recorded without patient identifiers 
to maintain confidentiality. Data analysis consisted of quantitative analyses.  
 
Results: 
A total of 100 patient charts were reviewed. Of those 100, 73 patients had their ART regimens mod-
ified. Of those 73 ART regimen changes, 54 were for safety related reasons (such as to avoid drug-
drug interactions or to mitigate adverse drug reactions), 20 were for simplification reasons (such as 
to decrease pill burden), and 6 were related to improving efficacy due to genotype resistance test-
ing. Some patients had their ART regimens changed for more than one reason. Of the 100 patients, 
75 patients were living with HIV, 18 were on PEP, and 7 were on PrEP. Nearly half (49) were en-
rolled in MAPs with pharmacist assistance. Most patients’ HIV VLs and CD4+ cell counts improved 
or stayed the same (89% VL and 79% CD4+). Few changes were made to co-morbid disease state 
medications (9 total modifications). Only 7 patients required coordination of care interventions.  
 
Conclusions: 
Because HIV medicine is so complex, there can possibly be a mentality of “don’t change what is 
working” when it comes to which ART regimen patients are on. Leaving patients on the same regi-
men for years and decades may lead to medication related problems. Pharmacists are uniquely 
trained to help mitigate medication related issues. This study appears to show that pharmacists are 
most valuable in HIV medicine in mitigating safety concerns (drug interactions and adverse drug 
events). Pharmacists may also be especially useful in enrolling patients in MAPs.   
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52.  Standardizing Specialty Pharmacist Follow-up Frequency in Patients Prescribed  
Inflammatory Disease-Modifying Therapies 
Rochelle Castrillo, PharmD, Linda Huynh, PharmD, Tara Berkson, PharmD,  
Adam Saulles, PharmD, CSP, BSACP 
 
Purpose:  Specialty medications for inflammatory conditions have demonstrated decreased effectiveness, 
safety, and quality of life, largely attributable to inadequate medication adherence. Furthermore, with poorer 
health outcomes, patients face greater healthcare costs associated with exacerbations, flares, and hospitali-
zations. Monitoring for non-adherence, side effects, and health status changes is essential for patients diag-
nosed with inflammatory conditions. The benefit of a standardized pharmacist clinical follow-up assessment 
is currently lacking in specialty pharmacy literature. This study will implement a standardized pharmacist fol-
low-up frequency guide and determine its clinical value and utility for patient safety and therapeutic goals in 
newly established patients diagnosed with inflammatory conditions. 
 
Methods:  A standardized follow-up frequency adjustment guide based on patient-specific factors, such as 
patient adherence, side effects experienced, and therapy efficacy was provided to all pharmacists where clin-
ical consultations should be conducted at month 0, 1, and 4. After the implementation of the pharmacist 
guide, the electronic health system record was reviewed for all patients who received an inflammatory condi-
tion new patient consultation between August 5th, 2019 and October 4th, 2019. Pharmacist consultations are 
conducted by utilizing pre-designed assessment forms, the “New Patient Inflammatory Assessment” for initial 
consults and the “Specialty Medication Management Services (SMMS) Inflammatory Assessment” for follow-
up assessments. How often pharmacists consistently stay within the standardized follow-up intervals versus 
how many times they deviate from the guide for patient care or safety reasons will be evaluated as the pri-
mary outcome. Secondary outcomes include categorizing and assessing the reasons for pharmacist devia-
tion, assessing quantity and types of pharmacist (RPh) interventions made during deviations from the guide 
by medication and condition, evaluate patient reported medication adherence, quality-of-life (QoL) metrics, 
and pharmacist time spent per assessment. Patient-reported QoL was reported on a scale of 0 to 10, with 0 
representing the best QoL and 10 representing poor QoL. 
 
Results:  There were a total of 154 patients enrolled into the study. Out of the 185 completed follow-up as-
sessments, 36 were deviations. The reasons for pharmacist deviation from the guide included inability to 
reach the patient during standardized follow-up frequency (41.7%), RPh clinical decision that sooner follow 
up was necessary (27.8%), patient initiated consult (25%), and RPh failed to attempt follow-up consultation 
at month 1 and/or 2 (5.6%). Pharmacist interventions occurred predominantly at month 0 (71.7%), month 1 
(15.5%), & month 4 (6.6%). The most frequent pharmacist interventions during consult deviations comprised 
of medication reconciliation (37%), and side effect management (33%), the remaining interventions were 
equal to or less than 7%. Following the initial assessment, the medication adalimumab and inflammatory 
condition psoriatic arthritis required the most pharmacist intervention at 32.2% and 21.5% of all follow-up in-
terventions, respectively. However, it was tofacitinib and ankylosing spondylitis, which required the most 
pharmacist consultation time. Tofacitinib averaged 13.2 minutes and ankylosing spondylitis averaged 15.2 
minutes per consultation. Patients taking adalimumab reported missed or late doses most frequently (33.3% 
of the 24 reported). Although QoL metrics were not consistently reported, there is a notable improvement 
from baseline to month 4. At month 0, the average patient-reported QoL was 5.6, while after 4 months of 
treatment, QoL scores improved to 3.6.  
 
Conclusion:  The standardized pharmacist follow-up frequency guide has provided a clinically meaningful 
strategy to monitor and follow-up with patients prescribed high-cost, high-risk inflammatory disease-
modifying therapies. By establishing that the majority of clinically significant interventions occurred during the 
standardized frequency intervals, this guide accomplished maintaining patient safety, in addition to aiding 
patients with their clinical goals and overall quality of life. In addition, this data supports continuing a standard 
follow-up frequency at month 1 and 4 by demonstrating that no critical interventions were missed and most 
deviations occurred due to pharmacist’s inability to reach patients during the pre-defined intervals. Although 
most pharmacist interventions occurred at the recommended intervals, it is important to consider patient-
specific factors when determining follow-up frequency. Thus, it is reasonable for specialty pharmacists to uti-
lize a standardized follow-up frequency guide that allows modifications based on clinical judgment to manage 
patients diagnosed with an inflammatory condition. 
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53.  PD-1 and PD-L1 Inhibitors:  
A Single Center Medication Assistance Program (MAP) Experience 
 
Sarah Tu, PharmD and Shuntao Cai, PharmD, BCOP 
Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA 
 
Background: PD-1 and PD-LI inhibitors are a large component of the growing immuno-oncology 
field and every year there are increasing studies investigating potential indications for these agents. 
This IRB approved retrospective chart review examines patients in the Medication Assistance Pro-
gram (MAP) within a large tertiary medical center who are on PD-1 and PD-L1 medications due to 
financial barriers and/or non-FDA approved regimens (unlabeled indications). This study seeks to 
evaluate efficacy and safety of PD-1 and PD-L1 for unlabeled vs labeled indications within this pop-
ulation. 
 
Methods: One hundred MAP patients treated with the PD-1 and PD-L1 inhibitors Opdivo 
(nivolumab), Keytruda (pembrolizumab) and Imfinzi (durvalumab) from October 2017- August 2019 
will be analyzed in a reverse chronological order. The following data will be collected from the EMR: 
patient age, gender, medication, indication, duration of therapy, duration of therapy, labeled or unla-
beled usage, if patient had a response, time to disease progression, concurrent therapies, total 
amount of drug administered, noted side effects, and if the FDA indication has changed since initia-
tion. Labeled indications will be defined as medications that are FDA approved for the patient ’s can-
cer type at time of medication initiation. Unlabeled medications are those not FDA approved for a 
patient’s cancer type at time of medication initiation. Evaluation of provider notes, lab tests and 
medication history records will be the primary data source for information collected. Primary objec-
tives include evaluation of labeled vs unlabeled indications for PD-1 and PD-L1 inhibitors. Second-
ary objectives include determining time to disease progression, incidence of adverse drug reactions, 
and financial impact for institution and patient. 
 
Results: Out of one hundred patients analyzed, 20% were on PD-1 and PD-L1 inhibitors for labeled 
indications and 80% patients were treated for unlabeled indications. The top three indications for 
PD-1 and PD-L1 inhibitors overall were head and neck (35%), gastroesophageal (17%), and breast 
cancer (12%) which was primarily driven by unlabeled patients. In stage IV head and neck, gas-
troesophageal, and NSCLC, unlabeled PD-1 and PD-L1 inhibitors demonstrated a greater average 
time to disease state progression compared to labeled indications (8.6 vs 7.3 months, 2.7 vs 1.1 
months and 12.9 vs 0.5 months). The percentage of patients with grade 2 and 3 toxicities were 
comparable between the unlabeled and labeled indications with total incidence of ADR at 45% for 
labeled indications and 46.3% for unlabeled indications. The most common ADR requiring medica-
tions or delay of therapy was hypothyroidism (25% in labeled and 20% in unlabeled). 
 
Conclusions: The majority of MAP patients are on PD-1 and PD-L1 inhibitors for unlabeled indica-
tions with the highest usage of Opdivo (nivolumab) at 74%. From our small sample size, there is 
promising data that PD-1 and PD-L1 inhibitors may prolong survival for several months longer for 
various indications including breast cancer, stage IV head and neck, gastroesophageal and 
NSCLC. These indications may later be incorporated into clinical trials as these agents seek new 
drug approvals. 
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54.  Impact of real-time antimicrobial stewardship team intervention versus conventional  
microbiology reporting on time to appropriate antimicrobial therapy in patients with  
Enterobacterales bacteremia. 
Scott C. King, Alyssa B. Christensen, Brent W. Footer, Timothy G. Shan, Kim Health,  
Ivor Thomas, and Margret Oethinger  
 
Introduction: 
The benefit of rapid laboratory speciation combined with real time antimicrobial stewardship team 
(AMT) interventions has been shown to improve patient outcomes and decrease hospital costs. The 
Providence Oregon region conducts direct from blood culture matrix-assisted laser desorption/
ionization time of flight (MALDI-TOF) identification, which results in decreased time to organism 
identification. The MALDI-TOF identification has allowed the AMT to intervene earlier than a health 
system using standard MALDI identification or comparable methods.  The purpose of this study is to 
assess the impact of real time notification plus AMT intervention on clinical outcomes in patients 
with Enterobacterales blood stream infections (BSI). 
 
Methods:  
This was an IRB approved, retrospective, multi-center, pre- and post- quasi-experimental study con-
ducted at eight acute care hospitals in the Providence Health & Services Oregon region. Adult pa-
tients (>18 years old) with a diagnosed BSI caused by an  Enterobacterales  species were included. 
The control group was from August 2018 to January 2019 and the intervention group was from Feb-
ruary 2019 to June 2019. Patients were matched based on age, gender, and admission to the ICU. 
Exclusion criteria included polymicrobial infection, Pitt bacteremia score >1, unable to take PO ther-
apy, and patients discharged to hospice care. 
During the intervention period the AMT members received real-time alerts for all blood culture spe-
ciation via a paging system. These cases where then reviewed and recommendations were made 
to the primary care team based off an approved protocol. The primary outcome for the study was 
time to de-escalation of therapy. Secondary outcomes include hospital length of stay and total dura-
tion of therapy.   
 
Results: 
A total of 60 patients were include in this study: 30 patients in the pre-intervention group and 30 pa-
tients in the post-intervention group. The most common age group was patients 60-69 years of age 
(43% vs 43%). The most common causative organism for the BSI was found to be Escherichia coli 
(76.7% vs 50%). During the intervention period a decrease was noted in median time to de-
escalation of therapy (2.7 days vs 1.8 days, p=0.0061) and length of stay (5.3 days vs 4.3 days, 
p=0.0475). There was no statistical difference in the total length of therapy (combined inpatient and 
outpatient duration) noted between the two groups (9 days vs 9.5 days, p=1). 
Conclusion: 
The results show a statistically significant decrease in both time to de-escalation and length of stay 
within the intervention group due to AMT recommendations. This is in line with previous studies and 
also highlights the benefit de-escalation could have on length of stay in the hospital. Studies with 
larger samples sizes should be considered to further explore these results.  
 
IRB Status:   Approved  
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55.  Manual scalp cooling in early stage breast cancer: value of caretaker training and  
patient-reported experience to optimize efficacy and patient selection 
 
Manaz Rezayee, BS, Nicole Moxon, RN, Staci Mellinger, RN, Amanda Y. Seino, Nicole E. Fredrich, 
Tracy L. Kelly, Susan Mulligan, MA, Patrick Rossi, MD, Ijeoma Uche, MD, Walter J. Urba, MD PHD, 
Alison K. Conlin, MD MPH, Janet Ruzich, DO, David B. Page, MD 
 
Alopecia is an emotionally distressing common adverse effect of curative-intent chemotherapy in 
early stage breast cancer.1–6 Although machine-based scalp cooling is effective for reduction of 
chemotherapy-associated alopecia in early stage breast cancer, availability is geographically lim-
ited.7–11 Manual cold-cap systems may also be effective and are available regardless of geograph-
ic location.12–14 We evaluated the feasibility of caretaker-administered cold-cap efficacy following 
structured standardized training, and utilized patient-reported subjective outcomes to develop a clin-
ical tool to facilitate patient selection.  
 
Patients and Methods:  
A small pilot study (n=10) was conducted to evaluate the feasibility and efficacy of manual cold cap-
ping. Key eligibility criteria included: 1) no hair loss at baseline; 2) no pre-existing scalp condition; 3) 
planned curative-intent chemotherapy for early stage breast cancer and 4) availability of caretaker
(s). Participants received standardized training and then performed the cold-cap procedure without 
assistance. The primary endpoint was post-treatment hair retention using Dean’s alopecia scale, 
with success defined as <50% hair loss. Secondary patient-reported outcomes (PROs) included 
QOL assessments (EORTC QLQ-C30, QLQ-BR23 and BIS), toxicity and subjective experience 
(obtained by standardized exit interviews).  
 
Results:  
Of the evaluable patients, 80% (n=8/10) met the primary efficacy endpoint (Dean’s scale 0-2) with 
20% (n=2/10) trial failures due to pre-mature discontinuation. Manual cold-capping was worthwhile 
to 90% of patients (Was it Worth It? Questionnaire) and associated with favorable PROs. Patient 
interviews identified a number of themes shared by almost all patients, which were subsequently 
used to develop a questionnaire to aid patient-directed decision-making on whether to pursue man-
ual cold-capping. 
 
Conclusion:  
This study affirms the safety and efficacy of manual cold-capping to reduce alopecia and demon-
strates the importance of proper training and education to maximize efficacy. It also highlights the 
considerable costs and effort associated with cold-capping. Selected patients with early stage 
breast cancer may benefit subjectively from cold capping while the proposed clinical instrument can 
be used to facilitate an informed discussion between patient and provider. 
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56.   Implementing a simplified targeted feedback method to reduce fluoroquinolone  
prescriptions in emergency departments 
 
Minh Le, PharmD, Alyssa Christensen, PharmD, BCIDP, Brent Footer, PharmD, BCPS 
 
Background: The CDC has proclaimed antibiotic resistance to be one of the biggest public health 
challenges of our time. Although fluoroquinolones (FQs) are among the most widely prescribed anti-
biotics in the ambulatory setting, there have been recent efforts to reduce their usage due to mount-
ing concerns regarding their safety profile and resistance patterns. Provider audit-and-feedback has 
been shown to be among the most effective antimicrobial stewardship interventions, but the auditing 
process requires significant healthcare resources, is time consuming, and must be continuous in 
order to have sustained durability. The purpose of this study is to determine if targeted provider 
feedback and education material can reduce FQ prescriptions independent of prospective auditing 
and feedback. 
 
Methods: This is an ongoing, multicenter, quasi experimental study across all emergency depart-
ments of a large healthcare system within the Oregon region. The primary objective is to decrease 
overall FQ prescriptions. Secondary objectives include reduction of FQ prescriptions by individual 
prescriber and study site. Pre-intervention antibiotic data was gathered between October and De-
cember 2019. Aggregate FQ prescription data was extrapolated by individual prescriber and study 
site and distributed in January. Education material containing the latest guideline recommendations 
and relevant practice pearls was also provided. Post-intervention data was then gathered between 
February and March 15. This study has been approved and given exempt status by the institutional 
review board.  
 
Results: There was a total decrease in both FQ and all antibiotic prescriptions in the post-
intervention period. Total encounters in which a FQ was prescribed was significantly lower in the 
post-intervention period with a difference of 2 (95% CI 1.6 to 2.3; p <0.0001). Using a McNemar test 
to account for low FQ prescription volumes, wherein monthly FQs were counted in binary units (0 or 
> 1 FQ prescriptions) for each provider, there was a statistically significant reduction in FQ rates 
from 140 providers (78.2%) in the pre-intervention period to 66 (39.3%) in the post-intervention peri-
od (p-value=0.0084). There was not enough data to perform statistics on FQ rates per provider or 
between study sites. 
 
Conclusion: Targeted provider feedback led to an overall decrease in FQ prescriptions. Although 
the preliminary results are encouraging, more data is needed to detect the true impact of the inter-
vention and analyze trends. 
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57.  Addressing The Social Determinants of Health in the Clinic Setting 
 
Larissa Sharma, MD, Man Tran, MD 
 
INTRODUCTION:  It is estimated that clinical care accounts for only 20% of health, while behaviors, 
physical environment, and social and economic factors determine the rest. The social determinants 
of health include the basic life needs of housing, food, transport, along with other factors that in-
clude employment, education, drug and alcohol use, dental and eye care, etc. Insecurity in these 
socioeconomic factors are expressed in chronic medical illness, mental health problems, substance 
use, all leading to high healthcare utilization. Healthcare costs and utilization decrease when when 
these needs are provided for. In a survey of 6,000 Providence patients, 50% expressed a social de-
terminant need. Providence subsidizes Community Resource Desks around Oregon, staffed with bi-
lingual resource specialists from local social service organizations, designed to connect individuals 
in need of support with resources available in their community. A model for referral to a local Com-
munity Resource Desk was created and patients referred to the desk to provide for any social 
needs.  
 
OUTCOMES:  More than 250 of our Providence St Vincent Resident Clinic patients were referred 
and offered resources in the 1st year of the project. At peak screening 30-40 patients were referred 
monthly. Most of these patients would not have otherwise come to our attention. Most common re-
sources provided: dental care, housing/rent, utilities, food, transport, employment assistance, health 
insurance, English/computer classes. We are better able to care for our most vulnerable patients 
including non- English speakers, uninsured, and Medicaid/Medicare patients. Clinic staff and provid-
ers expressed satisfaction with the simplicity of the process. 
 
DISCUSSION: ● This system allows for more comprehensive care, streamlines workflow for provid-
ers, and allows providers to practice in a way more in line with their goals. In addition, multiple stud-
ies show cost savings benefits to implementing similar programs. ● One study with a similar inter-
vention noted 10% yearly health care cost reduction for those who had their social needs met. ● 
Vermont Health system- implemented multidisciplinary team care model adding Community Health 
Specialist. Found tremendous cost benefits and decrease in hospital admission rates(declined 21%) 
and ED utilization(declined 31%). Per person per month costs fell 36%. ● We are in the process of 
collecting data on how this is impacting our quality metrics including healthcare utilization, hospitali-
zation rates and per patient/per month costs. 
 
Link to Poster 
 
58.   Battling the Stigma:  HIV Screen in Resident Primary Clinic 
 
Garrett Spencer, MD, Laura Loetscher, MD, Shelley Sanders, MD 
 
NTRODUCTION: HIV affects ~1.2 million in the US, with 25% unaware of their statusand annual 
incidence of 50,000. Early detection and treatment reduces risk of AIDS-related deaths and trans-
mission. Both the CDC and the US Preventative Service Task Force recommend routine HIV 
screening. The Providence Medical Group at St Vincent (PMG-STV) resident clinic has no routine 
screening protocol. • 24% (757/3139) of all clinic patients have ever been screened. • Of active clin-
ic patients seen quarterly, 5% are offered screening with only 3% completing screening. We imple-
mented and measured a clinic-wide HIV screening protocol leveraging existing clinic workflows. We 
aimed to increase screening of active clinic patients from 3% to 25% at one year. 
 
METHODS: Using a time-series design we measured quarterly rates of HIV screening tests ordered 
and resulted in active clinic patients, ages 18-65 and seen in office, during the study period. We uti-
lized a pre-existing preventative healthcare workflow for routine cancer screening, influenza vac-
cines, etc. We introduced this workflow to residents and staff prior to our go-live date. 
 
RESULTS / DISCUSSION: Our primary outcome was to increase quarterly HIV screening rate of 
active patients, with a secondary outcome to increase overall clinic HIV screening rate. We in-
creased the quarterly screening rate of active patients from 3.34% to 9.19%  
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59. Delirium:  Delirious Elders, Implementing Reduction Interventions Using Mobility 
 
Michael Silvas, MD, Joe Miller, MD, Shelley Sanders, MD 
 
INTRODUCTION: This quality improvement project involved hiring, training, and managing 3 Deliri-
um Mobility Aids to implement a non-pharmacologic delirium prevention bundle package, including 
early mobility, on hospitalized patients age >65. 
 
Background: Delirium affects 20-30% of older hospitalized patients [1]. Patients with delirium have 
double the mortality rate [3], which increases with delirium duration [4]. Delirium worsens long term 
cognitive functioning [9,10,11,12]. Hospital costs increase by $2,500 per patient, totaling 
$6,900,000,000 in Medicare expenditures [7]. A single delirium episode increases total yearly costs 
by ~$64,421 [2]. Research suggests the best treatment is non-pharmacologic multicomponent inter-
ventions [6], and those with most benefit include early mobility, reorientation, cognitive/sensory 
stimulation, and hydration [5]. 
 
Methods: A delirium prevention protocol was created addressing four main pillars. • Hydration: wa-
ter placed within patient reach. • Sensory input: • window blinds opened by 9:00 am • hearing-aids 
and eye-glasses retrieved and utilized. • Soothing music via delirium TV channel for non-
communicative patients. • Reorientation: oriented to person/place/time 3 times daily. • Mobility: 20-
min walk (mobilization event) 3 times daily Work and time constraints prohibited existing health pro-
fessionals (CNA, RN, MD, PT, OT) from implementing the protocol. Thus a new job position 
(Delirium Mobility Aid) was created to implement this protocol for all patients age >65 admitted to 
Medical A(28-bed medical unit). This was proposed to Providence St. Vincent Medical Foundation 
who awarded a $170,000 institutional grant for 12 months. The project residents reviewed applica-
tions, interviewed, and hired 3 CNA's to fill the position 12 hr/day, 7 days/week. Physical and Occu-
pational Therapy trained the aids for 3 weeks in delirium management and mobilization techniques. 
Data was collected in Epic flowsheetsand chart notes. Confusion-Assessment-Method (CAM) is a 
established delirium scoring system utilized on Medical A. Data from intervention year (2019) was 
compared to baseline data collected 2 years prior (2017, 2018) on the same hospital unit. 
 
Results: Preliminary data collected at month 9 of 12: • No statistically significant change in total de-
lirium burden. However there is a trend toward decreased delirium in prolonged hospitalization 
(measured after day 4). For these patients with LOS > 6 days, there was a 4% reduction in late-stay 
delirium compared to 2018 and 10% from 2017. • 7.5-13% more patients were completely delirium 
free after day 4 • Length of Stay (LOS): no significant change (5.5 days) • Patients admitted from 
home experienced a 4% increase in discharge to home (rather than care-facility) approaching near 
significance (p-value 0.06). • There was a trend toward reduction in hospital falls: 2017-33. 2018-29. 
2019 (present)-19, projected to reach 25 by year’s end. • Press-Ganey patient satisfaction scores 
remained stable. 
 
Conclusion: Non-pharmacologic multicomponent prevention protocols, which include mobilization, 
implemented by specialized CNA’s, are a potentially viable treatment of delirium in elderly patients 
with prolonged hospitalization. This may increase rate of discharge to home, without worsening 
falls, LOS, or patient experience, and has a cost-savings benefit. 
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60.  Impact of academic detailing on clinical pharmacy specialist involvement in medication as-
sisted treatment for opioid use disorder in a primary care setting  
  
Lindsey Bartos, PharmD; Kristin Tallman, PharmD, BCPS, BCACP;  
Dara Johnson, PharmD, BCPP, BCACP  
  
Introduction: Opioid prescribing and opioid overdose deaths have increased steadily since the 1990s, 
reaching a 6-fold increase between 1999 and 2017. The opioid crisis, as it became known, was de-
clared a public health emergency in 2017. In 2018 alone, an estimated two million people had a diag-
nosed opioid use disorder (OUD). The use of medication-assisted treatment (MAT) for OUD reduces 
the use and cravings of opiates, and risk of all-cause and opioid-related mortality. The inclusion of clin-
ical pharmacy specialists (CPSs) on multidisciplinary healthcare teams has been shown to improve 
health outcomes, increase cost-effectiveness, and improve the quality of healthcare. Nevertheless, 
CPS involvement in MAT for OUD in a primary care setting remains limited. This study will provide in-
formation regarding barriers to CPS involvement in MAT, and the effectiveness of academic detailing 
provided to CPSs in increasing CPS involvement.  
  
Objectives: The objectives of this project are to identify and describe the most common barriers to 
CPS involvement in MAT for OUD, then assess the impact of academic detailing on CPS comfort level 
with being involved in the care of patients undergoing MAT for OUD in the primary care setting. Addi-
tionally, this project will assess the hypothesis that academic detailing will increase the number of pa-
tients with a CPS involved in the treatment of OUD.  
  
Methods: Study participants are CPSs recruited from a large medical group in Oregon and SW Wash-
ington who completed a survey before and after participating in academic detailing. The presurvey was 
used to assess demographics, current involvement with MAT, perceived barriers to involvement in 
MAT, and asked participants to anonymously assess their comfort level, knowledge, and beliefs re-
garding MAT for OUD using a 0-5 point scale. Academic detailing was developed based on reported 
barriers, and consisted of handouts, two 45 minute interactive presentations, and small group work 
with case-based application. Participants then filled out a post-survey to re-assess their comfort level, 
knowledge, and beliefs regarding MAT for OUD following academic detailing. Survey results were 
compared and summarized by using either % of respondents in each category or mean (standard devi-
ation) for each question across all respondents, then compared using a Wilcoxon-rank-sum test. CPS 
involvement in MAT will be reassessed using a survey or electronic intervention tracking in June.  
  
Results: 19 CPSs responded to the pre-survey and 20 CPSs responded to the post-survey. 4 re-
spondents (21.05%) were currently active in MAT, and of these respondents, 3 indicated they are in-
volved with MAT for 1-5 patients annually, and 1 indicated they are involved with MAT for 20+ patients 
annually. The most common barriers to involvement in MAT were lack of time (23.08%), lack of X-
waivered providers (23.08%), and lack of knowledge regarding MAT (21.15%). There was no change 
in the number of CPSs involved in MAT between the pre-survey and the post-survey. Median respons-
es to 6 of the 8 survey questions differed significantly between the pre and post surveys (p<0.05), 
while the remaining 2 demonstrated improvement that was not statistically significant.  
  
Conclusions: Most CPSs within PMG are not involved in the use of buprenorphine in MAT for OUD, 
likely due to a combination of time constraints, a lack of providers with the ability to prescribe bupren-
orphine, and unfamiliarity with buprenorphine in MAT. Following academic detailing to address these 
barriers, CPS comfort with buprenorphine in MAT had significantly improved in most areas. CPS in-
volvement in MAT for OUT will be reassessed in June, 3 months following the academic detailing inter-
vention.  
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 61.   Increasing Vaccination Rates of children up to 24 months old at  
PMG Milwaukie Family Medicine 
 
Justin Ferley DO; Rachel Jackson MD; Aubrey Miller MD; Sebastian Reeve MD; Christelle Serra 
Van-Brunt DO; Jamie Skreen DO; Jeffrey Sun DO; John Yates MD; Daniel Ruegg MD 
 
Introduction: Each year in the US, 42000 adults and 300 children die of vaccine preventable dis-
eases. Yet across the country, clinics – including ours – fall short of the CDC Healthy People 2020 
goals of pediatric vaccination rates. This resident-led quality improvement (QI) project aimed to im-
prove our clinic vaccination rates in the under 24mo population. 
 
Methods: We identified 3 opportunities for vaccinating children under our clinic current processes: 
well child visits, medical assistants’ vaccinations visits, and acute care visits. Using a multidiscipli-
nary approach comprising residents, MAs, clinical care coordinators and our nursing quality supervi-
sor, we analyzed our current vaccinations processes and our iterative plan-do-study- cycles (PDSA) 
included: PDSA #1: standardize our work flow for vaccine reconciliation. PDSA #2: sending personal 
reminder lebers to patients and overall improving our vaccine recall/ reminder system. PDSA #3: 
Minimizing provider variation for vaccines given at the 12-18mo WCC. 
 
Results: We saw an improvement in our vaccinations rates after personalized reminder letters were 
sent out, outlining that we do not have a reliable vaccine schedule reminder system. We also noted 
that different providers created different vaccinations schedules in order to prevent giving 5 vaccines 
at the same $me – with no system in place to follow on missed vaccination, thus creating missed op-
portunities and suggesting that we need to implement a clinic-wide vaccine schedule. 
 
Conclusion: Our last PDSA cycle was interrupted by current CIVD-19 pandemic. We have however 
found valuable data to help improve our clinic’s vaccination rates, and plan to continue this project 
over the next 2 years. 
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62.   Evaluation of Transitional Care Interventions from a Decentralized Clinical  
Pharmacist in a Small Inpatient Geriatric Psychiatry Unit 
 
Nathan Wong, PharmD; Michael Brown, RPh, BCPS, BCPP 
 
Background:  
Transitioning between healthcare settings increases the risk for medication errors. A systematic review 
of 26 studies comparing various medication reconciliation interventions demonstrated consistent reduc-
tions in adverse drug events. Intensive pharmacist involvement and focus on high risk populations were 
the most successful. 1 Geriatric and behavioral health populations are especially vulnerable with 
polypharmacy and cognitive impairment often complicating the picture. Providence Milwaukie Hospital 
(PMH) houses a small unit tailored to provide mental health care for seniors. A certified psychiatric phar-
macist is nested within the team and plays a critical role in transitional care by reconciling medications 
upon admission and discharge. This study quantifies these interventions with the purpose of both estab-
lishing a baseline and identifying potential areas for future quality improvement projects. 
 
Methods:  
This is a single center retrospective chart review of all patients discharged from the Providence Milwau-
kie Hospital Senior Psychiatric Unit from January 1st, 2019 to January 1st, 2020. The unit contains 19 
private rooms for patients typically 65 years and older. Short term psychiatric care is provided by a di-
verse set of mental health professionals. The primary outcome evaluates in-unit changes made upon 
pharmacist reconciliation of admission and discharge medication lists. The secondary outcome evalu-
ates the occurrence of pharmacist medication counseling upon discharge. Patients with no existing prior 
to admission medication list or whose list was recently reconciled by a pharmacist prior to admission 
were excluded. This study has been approved by the Institutional Review Board.  
 
Results: 
A total of 254 discharges occurred from January 1st, 2019 to January 1st, 2020. Baseline characteristics 
included an average age of 75 years with a higher proportion of females at 66.1%. The average length 
of stay was 25 days and the most frequent discharge disposition was to home or self-care. Admission 
medication lists were reconciled either by a PMH pharmacist or an external pharmacist within 14 days of 
admission in 239 (94.1%) discharges. Inclusion criteria was met in 109 (42.9%) discharges. In unit phar-
macist medication reconciliation on admission totaled to 97 (89.0%). On admission, at least one discrep-
ancy was identified upon 70 (72.2%) reconciliations. A pharmacist on average added 2.8 drugs, re-
moved 1.7 drugs, and modified 1.2 drugs per reconciliation. Of the drugs that were modified, dosing and 
frequency changes were the most common. Each admission reconciliation included on average an addi-
tion, removal, or modification of 1.5 behavioral health medications. Upon discharge, reconciliation was 
documented in 74 (67.9%) cases and education was documented in 10 (9.2%). Implementing a proac-
tive education and reconciliation workflow upon discharge was recognized as an area where pharma-
cists may improve the effectiveness of transitions of care. 
 
Conclusions:  
Pharmacists are heavily involved in the transitions of care process for the Providence Milwaukie Hospi-
tal Senior Psychiatric Unit. An embedded clinical pharmacist is making impactful changes to patients ’ 
medication lists upon admission which often involve a behavioral health drug. Ensuring accurate medi-
cation lists enables providers to make informed decisions and reduces adverse events. 
 
1. Mueller SK, Sponsler KC, Kripalani S, et al. Hospital-based medication reconciliation practices: a 
systematic review. Arch Intern Med. 2012 Jul 23;172(14):1057-69. doi: 10.1001/
archinternmed.2012.2246. 
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63.   Evaluating the utility of CYP2C19 genetic testing for P2Y12 inhibitor prescribing  
within an inpatient setting 
 
Thomas Maslo, PharmD, Carolynn Null, PharmD 
 
The emergence of pharmacogenomics offers the opportunity to practice precision medicine across 
health care. In patients presenting with acute coronary syndrome (ACS) and undergoing percutane-
ous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is routinely prescribed for 12 
months. DAPT consists of a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) plus aspirin. Of the 
P2Y12 inhibitors, clopidogrel is uniquely impacted by CYP2C19 status. About 30% of the North 
American population carry at least one CYP2C19 allele associated with reduced metabolism. Ti-
cagrelor and prasugrel are not impacted by CYP2C19 metabolism, but are associated with in-
creased bleeding and cost. Current guidelines favor the use of the latter, with routine genetic testing 
not recommended. Recent studies have provided positive evidence that a genotype-guided ap-
proach results in improved outcomes. This study aims to identify how CYP2C19 genetic testing may 
impact prescribing practices. This is an IRB-approved, retrospective cohort analysis of P2Y12 inhibi-
tor prescribing and outcomes following PCI. Chart review within the electronic health record was 
completed from September 2016 to September 2019 among patients presenting to two large, tertiary 
medical centers. Patients included those >18 years old, with an index diagnosis of ACS. Patients 
were excluded if they had a history of cancer, pregnancy, or if they did not have a documented en-
counter after 30 days following PCI. The primary outcome was the incidence of optimal P2Y12 inhib-
itor prescribing. Secondary outcomes included major adverse cardiovascular events (MACE) and 
stent thrombosis at 30 days and 1 year. A cost analysis was also completed utilizing a simulated 
genotype-guided strategy.  A total of 401 patients were included within the primary analysis, with 
clopidogrel and ticagrelor being prescribed at rates of 73.1% and 26.1%, respectively. Prasugrel was 
prescribed at a rate of 0.8%. There was no difference among prescribing for an index diagnosis of 
NSTEMI vs. unstable angina (p=0.71). However, prescribing was different for NSTEMI vs. STEMI 
(p=0.00) and unstable angina vs. STEMI (p=0.00). Patients prescribed clopidogrel were readmitted 
for MACE or other ischemic events significantly more than those prescribed ticagrelor (p=0.01). Ad-
ditionally, event rates were increased within the initial 30 days. In a cost-analysis with a simulated 
genotype-guided strategy, reduced readmission rates resulted in total cost-savings of $527,377, or 
$1,325 per person. This study shows that overall P2Y12 inhibitor prescribing rates compare favora-
bly to the expected population distribution of CYP2C19 alleles. However, individuals with loss of 
function alleles are potentially being prescribed clopidogrel at discharge, thus increasing their risk for 
adverse outcomes. As these event rates are more pronounced within the initial 30 days, initiating 
CYP2C19 screening in the inpatient setting may help minimize early readmissions. Additionally, a 
genotype-guided approach may result in cost-savings over 1 year.  
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64.  Impact of clinical pharmacist medication review upon enrollment in a Program of All-
Inclusive Care for the Elderly (PACE) 
 
Adam Olesen, PharmD, PGY1 Resident, Kristen Wendell, PharmD, BCGP 
Providence Elderplace Oregon 
 
Learning Objective: 
Describe the interventions and recommendations made by a pharmacist upon enrollment of a new 
participant at a PACE facility. 
 
Abstract: 
Pharmacists have been proven to be beneficial in the transitions of care for high-risk patients with 
multiple morbidities, such as the reduction of both polypharmacy and thirty-day readmission rates. 
The objective of this study is to quantify and characterize the total number and type of interventions 
and recommendations made by pharmacists over a three-month span when new participants enrolls 
with Providence ElderPlace, a Program of All-Inclusive Care for the Elderly (PACE). Clinical phar-
macists at Providence Elderplace were trained on how to document their interventions and recom-
mendations within the EPIC electronic medical record using the I-vent documentation system. The 
pharmacists documented interventions made at the time of enrollment and recommendations for 
follow-up after enrollment for all participants who were enrolled between Nov 1, 2019 and Jan 31, 
2020. The primary investigator gathered this data via the I-vent reporting system within EPIC. Phar-
macists also documented whether each recommendation pertained to a Beers List medication and 
whether the recommendation is made with the primary goal of reducing polypharmacy. The primary 
investigator followed recommendations that were not implemented at enrollment for two months to 
assess whether they were implemented by the provider. Data was analyzed to quantify the impact 
of these recommendations and interventions that the clinical pharmacists had made. The primary 
endpoint was a composite analysis of the number and type of interventions completed upon enroll-
ment. Secondary endpoints included the percentage of recommendations presented by pharmacists 
that are implemented at enrollment and within two months following enrollment, whether the inter-
vention pertains to a medication on the 2019 Beers List, and the number of recommendations of 
which the primary goal was to reduce polypharmacy (defined as unused medications on an enrol-
lee's medication profile). Results will be presented. This study approved by the Institutional Review 
Board. 
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65.   Implementation and evaluation of pulmonary arterial hypertension clinical program  
and pharmacist education at a health-system specialty pharmacy 
 
Timothy Cao, PharmD, PGY-1 Pharmacy Resident, Adam Saulles, PharmD, CSP, BCACP and 
Tara Berkson, PharmD, BCACP 
 
 
Pulmonary Arterial Hypertension (PAH) is a progressive, debilitating, and costly disease, often re-
sulting in poor prognosis when treatment is inadequate. With an exponential growth of specialty 
therapies, clinical pharmacists in specialty pharmacies are well-equipped to play an integral role in 
improving patient care outcomes and reducing overall healthcare costs. By incorporating a PAH-
specific clinical program as part of the specialty pharmacy workflow, clinical pharmacists can pro-
vide meaningful interventions, such as evaluation of disease-modifying medications through individ-
ualized assessment of disease state symptoms, reconciliation of medications to assess for drug in-
teractions, and laboratory parameter, compliance with Risk Evaluation & Mitigation Strategies 
(REMS) programs, while dispensing medications in a safe and cost-effective manner. 
The purpose of this study was to develop and implement a PAH-specific clinical assessments and 
workflow, while providing enhanced pharmacist education, training & resources in a health-system 
specialty pharmacy setting. 
 
This was a single-centered, quasi-experimental and implementation study with retrospective review 
at a health system specialty pharmacy. The primary objective of this study centered on building 
PAH-specific “new patient” and “patient follow-up” assessments and providing specialty pharmacists 
enhanced PAH and REMS education and training. The effectiveness of pharmacist education was 
evaluated based on pre-and- post clinical assessments during two targeted training sessions before 
the launch of the new workflow, along with a final clinical assessment one-month post-workflow 
launch. The secondary objective of this study focused on the quality of patient intervention during 
the implementation phase and pharmacist satisfaction with PAH/REMS-focused education. A retro-
spective report was run from the specialty pharmacy electronic health record (EHR) from February 
2nd, 2020 to April 17th, 2020 for all completed PAH assessments and pharmacist interventions. 
Primary objective results found upward trend in pharmacist competency and readiness following two 
PAH/REMS education sessions. Clinical assessments during pre-implementation phase found aver-
age pre-test results of 43.5% and post-test results of 74%, indicating 70% increase in pharmacist 
competency. High level of proficiency was sustained one-month post-implementation phase with 
mean competency at 85% and above. Pharmacist readiness in PAH management increased by 
67% overall. Secondary objectives found majority of pharmacists were satisfied with the PAH edu-
cation, implementation process and resources provided. EHR retrospective review identified several 
meaningful pharmacist interventions, notably drug utilization and interaction reviews, lab parameter 
assessments, side effect management and medication educations. High cost, complex medication 
regimens were dispensed according to REMS criteria and delivered to patients safely within an av-
erage of 3.5 days to ensure patient continuation of therapy. 
 
PAH clinical program implementation and targeted- education successfully enhanced pharmacists’ 
clinical knowledge, readiness, and meaningful intervention for PAH population in a health-system 
specialty pharmacy. 
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66.   Impact of pharmacist-led appointments for hypertension management in a primary care 
setting: a retrospective analysis 
 
Anne Marie Thibodeaux, PharmD, MPH, Christing Doran, PharmD, MBA, BCACP 
Ben Rosait, PharmD, BCACP 
 
Introduction: 
High blood pressure is a major risk factor for heart disease and stroke, two of the leading causes of 
death for Americans.1 Evidence supports the idea that pharmacist-led hypertension management 
can result in overall blood pressure reduction; however, it remains unclear whether pharmacist-led 
initiatives can also improve performance metrics.2-5 
 
Research question: 
Can pharmacist-led appointments for blood pressure management positively impact hypertension 
metrics? 
 
Study design: 
Retrospective chart review 
 
Methods: 
Primary outcome data was measured via metric inventory, defined as percentage of patients who 
had reached their blood pressure goal. Two time points were compared at two primary care clinics 
(1 month before the pharmacist-led HTN appointments were established compared to 4 months af-
ter) to determine a potential change in percentage of patients achieving BP goal. Secondary out-
come data was obtained via chart review for patients whose hypertension was managed by the 
pharmacist (n=50) and matched patients managed by their primary care physician (n=50). 
 
Results: 
Overall, the metric for Clinic A decreased from 74.7% to 73.5%, and Clinic B decreased from 72.2% 
to 65.5%, illustrating less patients had achieved their blood pressure goal. However, a change in 
the metric definition occurred in the middle of the study period, which may explain the percentage 
decrease. Examining pharmacist visits, only 38% of patients were at their goal blood pressure ini-
tially, but 80% of patients were at their BP goal during their final visit. Pharmacists had an average 
of 2.2 medication interventions per patient per visit. 
 
Conclusions: 
The overall change in the metric does not suggest pharmacist-led appointments for hypertension 
management can positively impact the metric; however, changes in the metric definition interfered 
with proper assessment. Overall, pharmacists were able to optimize medication regimens, and al-
most half of the patients who were not at goal initially were able to achieve it within 4 months. 
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